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Regulatory T cells are essential for self tolerance and immune homeostasis. Lack of 
Teffector-cell function and gain of suppressive activity by Treg are dependent on the 
transcriptional program induced by FOXP3. Here we identified the repression of 
SATB1, a genome organizer regulating chromatin structure and gene expression, as a 
critical event for Treg phenotype and function. FOXP3 acts as a transcriptional 
repressor directly at the SATB1 locus and indirectly through induction of microRNAs 
binding to the 3′UTR of SATB1 as well as by maintaining a repressive chromatin state 
of the SATB1 locus. Release of SATB1 from FOXP3 control in Treg causes loss of 
suppressive function, establishment of transcriptional Teffector programs, and induction 
of Teffector cytokines in vitro and in vivo. These data support that inhibition of SATB1-





Treg are characterized by their suppressive function and inability to produce effector 
cytokines upon activation
1
. Expression of the X-linked forkhead transcription factor 
FOXP3 has been clearly linked to the establishment and maintenance of Treg lineage, 
identity and suppressor function
2-7
. Moreover, FOXP3 is also associated with the control of 
Teffector function in Treg
4, 5
. Although, there is a growing body of evidence pointing towards 
plasticity amongst committed CD4
+
 T-cell lineages including Treg
8-11
 the mechanism for 
this plasticity and its significance in normal immune responses and disease states are still to 
be elucidated. Naturally occurring functional deletion mutants of FOXP3 in man (IPEX 
(immune dysregulation, polyendocrinopathy, enteropathy, X-linked) and mice (scurfy) are 
associated with severe autoimmunity and excessive Teffector function
6, 7, 12, 13
. However, it is 
unclear whether autoimmunity occurs because the T cells destined to become Treg now have 
effector function (cell intrinsic) or whether there is lack of peripheral tolerance due to the 
lack of Treg (cell extrinsic). While these mechanisms are not mutually exclusive and could 
both contribute to immune dysfunction, there are new studies indicating that Treg can 
become potent mediators of autoimmunity when FOXP3 expression is lost. Multiple 
transgenic reporter mouse models have demonstrated that loss of FOXP3 can induce the 
conversion of Treg into cells with a variety of Teffector programs
2-4, 14
. In a model where 
FOXP3 is attenuated, a TH2 phenotype was induced in the Treg compartment
2
. In other 
transgenic models deletion of FOXP3 induced TH1, TH2, or TH17 phenotypes in FOXP3 
positive cells
4, 14
. While Treg seem to be re-programmable by loss of the lineage-associated 
transcription factor FOXP3, there is no evidence that conventional T cells (Tconv) actively 
suppress the Treg lineage program. On the contrary, only stable expression of FOXP3 in 
Tconv appears capable of inducing a Treg phenotype within these cells
7
. Together these 
findings suggest that Teffector programs are the default state in CD4
+
 T cells and that 
transcriptional programs induced and maintained by FOXP3 overrule Teffector function in 
5 
Treg. Whether the inhibition of Teffector differentiation in Treg is critical for Treg suppressive 
function is unclear. Such a model would be supported by the existence of FOXP3-induced 
mechanisms that continuously and actively control Teffector programs in these specialized T 
cells.  
Consistent with the active suppression of Teffector programs in Treg ablation of the 
transcriptional repressor Eos
15
 or the FOXO transcription factors
16, 17
 impart partial Teffector 




 have also 
been implicated in the modulation of effector cell differentiation by Treg
20
. Selectively 
disrupting miRNA control in Treg leads to ablation of Treg function and gain of effector 
function
21-23
 suggesting that there is additional posttranscriptional control sustaining Treg 
phenotype and function. There is also evidence that epigenetic control by DNA methylation 
and histone modification is important for FOXP3-mediated suppressive functions
18, 24, 25
 
raising the possibility that epigenetic regulation may also be involved in the repression of 
Teffector functions in Treg. Moreover, genome-wide assessment of histone modifications in T-
cell subsets indicated an unexpectedly high degree of plasticity between different T-cell 
subsets including not only effector populations but also iTreg and Treg
26
. In summary, these 
findings support the existence of active regulatory mechanisms that enable committed Treg 
to suppress Teffector differentiation
27
. The mechanisms identified so far are mainly associated 
with the induction of FOXP3-specific programs involved in the maintenance of Treg 
phenotype and function. However, complementary mechanisms preserving Treg function 
through the repression of a global process required for triggering Teffector function may also 
exist.  
 In this report, we specifically searched for genes repressed by FOXP3 in Treg that 
might be central to maintaining regulatory function and suppression of Teffector function in 
6 
Treg. We identified the special AT-rich sequence-binding protein-1 (SATB1) to be amongst 
the most significantly repressed genes in human and murine Treg. Repression was mediated 
directly by transcriptional control of FOXP3 at the SATB1 locus and indirectly by FOXP3-
dependent miRNAs as well as repressive histone marks. Release of SATB1 from FOXP3 
control was sufficient to re-program natural FOXP3
+
 Treg into Teffector cells that lost 
suppressive function and gained Teffector function in vitro an in vivo. These findings show 




SATB1 is expressed only at low levels in human Treg 
To identify regulatory circuits actively suppressed by FOXP3 as a prerequisite for 
Treg function and inhibition of Teffector programs, whole transcriptome analysis of human 









 T cells (Treg) was performed (Supplementary Fig. 1 and Supplementary 
Table 1). Of the 22 genes displaying significant downregulation in Treg, special AT-rich 
sequence-binding protein 1 (SATB1) was consistently expressed at a significantly lower 
level in Treg compared to Tconv (Fig. 1a). Re-assessment of transcriptome data from previous 




SATB1 is a chromatin organizer and transcription factor essential for controlling a 
large number of genes participating in T-cell development and activation
31
. SATB1 
regulates gene expression by directly recruiting chromatin modifying factors
32
 and 
anchoring matrix attachment regions to the nuclear matrix
33
. In murine TH2 clones, SATB1 
has been shown to function as a global transcriptional regulator specifically anchoring the 
looped topology of the TH2 cytokine locus, a pre-requisite for the induction of certain TH2 
cytokines
34
. Since SATB1-deficient thymocytes do not develop beyond the double-positive 
stage
31, 33
, the role of SATB1 in peripheral T cells, particularly in Treg, is still elusive. 
Transcriptome data were validated in an independent set of samples by qRT-PCR (Fig. 1b), 
western blotting (Fig. 1c), and single cell analysis by flow cytometry (Fig. 1d) clearly 
demonstrating reduced SATB1 mRNA and protein expression in human Treg. Since similar 
8 
results were obtained by the different techniques we further analyzed on single cell level 
using either analytical flow cytometry or cell sorting. As increased SATB1 expression has 
been previously linked to activation of pan-T-cell populations
35
, we assessed the dynamics 
of SATB1 expression in Tconv and Treg during activation using T-cell receptor stimulation 
(with CD3 mAbs) in the presence of co-stimulation (CD28 mAbs) or the cytokine 
interleukin-2 (IL-2) (Fig. 1e) as well as mitogens (data not shown). Analysis of SATB1 
expression established a stimulation dependent up-regulation of SATB1 in Tconv while 
resting Treg had a significantly lower SATB1 expression than Tconv and this expression was 
only modestly upregulated after T-cell activation. Next we assessed SATB1 in induced Treg 
(iTreg)
36




 T cells were activated via TCR and CD28 in the 
presence of TGF for 5 days. These iTreg expressed FOXP3 mRNA and protein, and 
showed T-cell suppressive function (data not shown). Similar to natural Treg, SATB1 was 
not induced in iTreg under these conditions while significantly enhanced expression was 
observed in cells stimulated via TCR and CD28 in the absence of TGF (Tstim, Fig. 1f, g). 
In line with this observation, TH1 and TH2 cytokine production is significantly abrogated 
in the absence of SATB1 (Fig. 1h). To determine whether FOXP3 induction in iTreg was 
necessary to suppress SATB1 we performed gain-of-function experiments ectopically over-
expressing FOXP3 in Tconv. High expression of FOXP3 resulted in reduced expression of 
SATB1 (Fig. 1i), which was accompanied by a concomitant decrease in cytokine 
expression (Fig. 1j) and the induction of a Treg-cell gene signature (Supplementary Fig. 2). 
Low level FOXP3 expression did not result in significant repression of SATB1 or induction 
of a Treg gene signature (data not shown). Taken together, reduced expression of SATB1 is 
9 
a hallmark of both iTreg and Treg in humans and repression of SATB1 depends on 
sufficiently high expression of FOXP3. 
 
Loss of FOXP3 in Treg results in high SATB1 expression 
To further assess the role of FOXP3 in SATB1 repression in human Treg we 
performed loss-of-function experiments. Silencing FOXP3 by siRNA resulted in loss of 
FOXP3 expression and consequently loss of suppressive function in Treg (Fig. 2a, b) as well 
as typical Treg-cell genes (Supplementary Fig.3). A small but significant increase of SATB1 
expression was already evident in unstimulated FOXP3-depleted human Treg (Fig. 2c), 
however, this was significantly enhanced when Treg were stimulated via TCR together with 
co-stimulation or IL-2. This increase in SATB1 expression was associated with production 
of TH1 (IFN-) and TH2 (IL-4 and IL-5) cytokines (Fig. 2d, e). As this effect could have 
been a direct effect of FOXP3 on the cytokines themselves we developed a strategy to 
knockdown SATB1 and FOXP3 simultaneously in human Treg. Only experiments with a 
sufficient knockdown efficiency for both genes were further analyzed. Additional 
knockdown of SATB1 in human Treg with a silenced FOXP3 gene (Supplementary Fig. 4) 
resulted in a significantly decreased induction of T-helper cytokines (Fig. 2f) demonstrating 
that expression of Teffector cytokines in FOXP3-deficient Treg is governed by SATB1. 
Similar results were obtained when expanded human Treg were transduced with lentiviruses 
encoding miRNA targeting FOXP3 and SATB1 (Supplementary Fig. 5). Together, these 
findings establish that FOXP3 negatively regulates SATB1 expression and that low SATB1 
10 
levels are required to prevent expression of Teffector cytokines in human Treg, thus assigning a 
key function of FOXP3-SATB1 interaction to the Treg phenotype.  
 
FOXP3 expression is not linked to low levels of SATB1  
 To exclude the possibility that SATB1 may reciprocally repress FOXP3 in Tconv 
cells we performed siRNA mediated knockdown of SATB1 in human naïve Tconv to assess 
whether SATB1 downregulation in Tconv might induce FOXP3 expression and a conversion 
of Tconv into Treg. We did not observe increased FOXP3 expression in resting and stimulated 
naïve Tconv, including under iTreg-inducing conditions after silencing of SATB1 
(Supplementary Fig. 6a), suggesting that high SATB1 levels are not necessary for low 
levels of FOXP3 in resting Tconv and that FOXP3 induction in naïve Tconv under stimulation 
occurs independent of the levels of SATB1. In line with this finding, we did not observe 
increased induction of several Treg-cell associated genes after knockdown of SATB1 
(Supplementary Fig. 6b). 
 
SATB1 expression in murine Treg 
To address whether SATB1 regulation is conserved between human and murine Treg 
we analyzed SATB1 expression by qPCR, western blotting, flow cytometry, and confocal 





). Similar to human Treg SATB1 mRNA and protein expression was lower in 
murine Treg compared with Tconv cells isolated from thymus, spleen or lymph nodes (Fig. 
3a, b, c, and data not shown). SATB1 expression in CD4
+
 single-positive thymocytes was 
considerably higher than in peripheral CD4
+
 Tconv from the spleen or lymph nodes (data not 
11 
shown) which further supports the essential role of SATB1 during early thymocyte 




. Despite this, FOXP3
+
 Treg in thymus still 
displayed a significant downregulation of SATB1 compared with FOXP3
-
 cells s.  
To establish SATB1 as a FOXP3-target gene we analyzed Treg from male DEREG 
mice harboring a spontaneously mutated FOXP3 allele (DEREG x scurfy). Flow-sorted Treg 
from these animals displayed a significantly increased SATB1 expression in Treg compared 
to FOXP3-competent Treg (Fig. 3d). In line with this finding an increase of TH1 and TH2 
cytokines in vivo was observed in Treg from DEREG x scurfy mice (Fig. 3e). SATB1 
mRNA expression in Treg versus Tconv cells was further validated by re-assessment of three 
transcriptome data sets (GSE18387, GSE6681, GSE11775)
5, 39, 40
 derived from mice with a 
mutated FOXP3 gene in Treg (data not shown).  
Female heterozygous DEREG x scurfy mice harbor both FOXP3-competent and 
FOXP3-incompetent Treg. These mice were used to determine whether SATB1 repression 
in Treg cells is a cell-intrinsic function of FOXP3. FOXP3-competent and FOXP3-
incompetent Treg were isolated and compared side-by-side by immunofluorescence (Fig. 
3f). Similar to previous reports we observed nuclear localization of SATB1 in FOXP3
-
 
thymocytes forming a cage-like structure within the nucleus (Fig. 3c)
33
. Increased SATB1 
signals in FOXP3-incompetent Treg cells with unchanged localization and distribution 





 Treg was further quantified by intracellular flow cytometry (Fig. 
3g). Overall, these data clearly establish increased SATB1 mRNA and protein expression 
as a consequence of FOXP3 deficiency in Treg. 
 
12 
FOXP3 binds to the genomic SATB1 locus in human Treg 
Inverse correlation between FOXP3 and SATB1 expression in murine and human Treg 
strongly suggested that FOXP3 might act directly as a transcriptional repressor of the 
SATB1 locus. We performed FOXP3-ChIP tiling arrays and promoter arrays using 
chromatin isolated from human natural Treg (Fig. 4a and Supplementary Fig. 7a) as well as 
bioinformatic in silico prediction to identify 16 regions for qPCR validation. Binding 
regions identified were located upstream of the TSS as well as in the genomic locus of 
SATB1 (Fig. 4b and Supplementary Table 2). FOXP3 binding within the promoter region 
or genomic locus of SATB1 in Treg was demonstrated by ChIP-coupled quantitative PCR 
(ChIP-qPCR) (Fig. 4c) and electrophoretic mobility-shift assays (data not shown) clearly 
demonstrating binding to the SATB1 locus similar to known targets of FOXP3 
(Supplementary Fig. 7b-f). To probe functional consequences of FOXP3 binding to the 
SATB1 locus, we performed luciferase reporter assays for six of the FOXP3 binding 
regions. FOXP3 binding regions were cloned in between a minP promoter element and a 
luciferase reporter gene. Co-transfection of these reporter constructs with a human FOXP3 
expression vector led to a significant decrease in activity for four of these regions with 
more than one FOXP3 binding motif (Fig. 4d). Mutation of predicted FOXP3 binding 
motifs within these regions rescued luciferase activity (Fig. 4d) indicating that SATB1 
expression is actively repressed by FOXP3 binding to several regions within the genomic 
SATB1 locus. Further support for FOXP3 binding was derived from in vitro DNA-protein 
interaction analysis using recombinant FOXP3 protein with either wild-type or mutated 
FOXP3 binding motifs within the BR1 and BR2 elements demonstrating strong binding of 
13 
FOXP3 only to the wild type sequences (BR1: KD 516.2 nM, BR2: KD 579.8 nM) whereas 
the mutated motifs showed almost no interaction with FOXP3 (Fig. 4e). 
 
Ectopic SATB1 expression in Treg results in loss of suppressive function and gain of 
Teffector function  
To determine whether reduced SATB1 expression is required for Treg to exert 







Treg using a lentiviral vector carrying the SATB1 full length transcript (Supplementary Fig. 








 Tconv were stimulated for 24 
hours with CD3 and CD28-coated beads in the presence of IL-2. After this initial 
stimulation, Treg were lentivirally transduced with pELNS DsRED 2A SATB1 which 
expresses DsRED at a ratio of 1:1 to the transgene
41
 or control virus containing only 
DsRED. Cells were expanded for 6 days in the presence of CD3 and CD28-coated beads 
and IL-2, prior to sorting DsRED-positive cells. Only SATB1 and control transduced cells 
showing highly similar FOXP3 and DsRED expression were used for further analysis 
(Supplementary Fig. 8a). In sharp contrast to control-transduced Treg, SATB1 over-
expressing FOXP3
+
 Treg cells lost their suppressive function (Supplementary Fig. 8b-c and 
Fig. 5a). At the same time, these cells gained expression of TH1 (IFN-), TH2 (IL-4), and 
TH17 (IL-17A) cytokines (Fig. 5b-e) suggesting a reprogramming of Treg cells into Teffector 
in the presence of high levels of SATB1 in the absence of any change in FOXP3 levels. As 
expected, Tconv transduced with SATB1 using the same approach had no suppressive 
14 
function (Supplementary Fig. 9). These data strongly support that ectopic expression of 
SATB1 in Treg is sufficient to convert the FOXP3-mediated program into Teffector programs. 
 
High expression of SATB1 induces transcriptional Teffector programs 
To estimate the genome-wide re-programming in SATB1 over-expressing Treg 
whole transcriptome analysis was performed. Using stringent filter criteria a total of 100 
genes were found to be significantly increased in SATB1 expressing Treg whereas 21 were 
decreased (Fig. 6a). Analysis of the differentially expressed genes revealed that 20% were 
associated with elevated expression in Tconv (in comparison to Treg), 29% of the changed 
genes were primarily linked with T-cell activation, and 16% were classified as common T-
cell genes. The remaining genes (35%) showed no known association with T-cell function 
or lineage and were classified as SATB1-induced (Fig. 6b). Furthermore, compiling gene 
lists previously associated with TH1, TH2, and TH17 differentiation revealed induction of 
many genes involved in Teffector differentiation in SATB1-expressing Treg (Fig. 6c).In 
contrast genes representing the human Treg-cell gene signature including the Treg-cell 
signature we identified, were unchanged in SATB1 expressing Treg (Fig. 6d). Since we used 
polyclonal human Treg for this analysis, it is not surprising that we find the three major T-
cell differentiation programs simultaneously. In summary, low SATB1 expression in Treg is 
necessary to permit suppressive function and to ensure inhibition of effector cell 
differentiation of regulatory T cells.  
 
Epigenetic regulation of SATB1 transcription in Treg 
15 
The strong dependency of Treg function on the repression of SATB1 implies the 
involvement of additional regulatory mechanisms. When assessing DNA methylation, we 
identified three CpG-rich sites upstream of exon 1 at the SATB1 locus (Fig. 7a). However, 
in contrast to the FOXP3 locus itself (Supplementary Fig. 10)
24
, the SATB1 locus was 
similarly demethylated in Treg and Tconv (Fig. 7a) suggesting that DNA-methylation does not 
play a regulatory role at the SATB1 locus in Treg.  
Next, we examined the chromatin status of the SATB1 locus by analyzing 
permissive and repressive histone modifications. ChIP-sequencing of expanded human Treg 
showed a reduction in permissive histone H3 trimethylation at Lys 4 (H3K4me3) and 
increased repressive histone H3 trimethylation at Lys27 (H3K27me3) in Treg compared to 
Tconv in humans (Fig. 7b and Supplementary Fig. 11) as well as lower acetylation of histone 
4 (H4Ac, Fig. 7b and Supplementary Fig. 11). Using CHIP-qPCR we confirmed these 
epigenetic differences between Treg and Tconv (Fig. 7c). When assessing a publicly available 
dataset for murine Treg we could establish similar histone marks at the SATB1 locus 
(Supplementary Fig. 12) suggesting that a conserved regulatory circuit exists that 
contributes to the lower expression of SATB1 in Treg by inducing repressive epegenetic 
marks at the SATB1 locus.   
 
MicroRNA-dependent regulation of SATB1 levels in Treg 
A prominent layer of post-transcriptional gene regulation is exerted by miRNAs. 
MiRNA profiling in human Treg versus Tconv allowed us to identify several differentially 
expressed miRNAs in Treg (data not shown). Using inverse correlation analysis between 
SATB1 and miRNA expression as well as computational prediction of miRNA binding of 
16 
seed-matched sites (Fig. 8a), we identified 5 miRNAs that were differentially expressed 
between Treg and Tconv (Fig. 8b) and showed a significant inverse correlation between 
SATB1 and miRNA expression (Fig. 8c). Of these 5 miRNAs, miR-155, miR-21, and miR-





confirmed by FOXP3-ChIP tiling arrays and ChIP-qPCR (Fig. 8d,e, and Supplementary 
Fig. 13) as well as functional analysis (Simon Barry, unpublished data). Assessment of 
miRNA expression levels in FOXP3-overexpressing Tconv and FOXP3-silenced Treg could 
confirm these miRNAs as targets of FOXP3 (Supplementary Fig. 14). For the assessment 
of functionally relevant binding of the miRNAs to the 3′ UTR of the SATB1 mRNA we 
fused the SATB1 3′ UTR to a luciferase reporter gene and determined luciferase activity in 
cells transfected with synthetic miRNAs. Expression of any of the 5 miRNAs significantly 
repressed constitutive luciferase activity with the 3 miRNAs that are direct targets of 
FOXP3 clearly showing the strongest effect (Fig. 8f). Mutation of the respective binding 
motifs resulted in restoration of luciferase activity (Fig. 8f). As exemplified for miR-155, 
loss of function of a single miRNA only resulted in minor differences in SATB1 mRNA 
expression in primary human Treg (Supplementary Fig. 15a) indicating that the loss of a 
single miRNA may be incapable of rescuing SATB1 expression. Complete loss of all 
miRNAs, however, as achieved in mice by a Treg-specific deletion of DICER
23
 clearly leads 
to up-regulation of SATB1 at both mRNA and protein level (Fig. 8g and Supplementary 
Fig. 15b). These results suggest that FOXP3 is able to confer Treg-specific downregulation 
of SATB1 expression not only by direct binding to the SATB1 locus but also using a 
second layer of regulation using miRNAs. 
17 
 
Decreased Treg-cell function in SATB1 expressing murine Treg in vivo  
To assess whether SATB1 expression results in reduced regulatory function in 





from DEREG mice using a lentiviral vector carrying the SATB1 full length transcript 








 Tconv from 
DEREG mice were expanded for 10-14 days with CD3 and CD28-coated beads in the 
presence of IL-2. After this initial expansion period, murine expanded Treg were lentivirally 
transduced with a SATB1-IRES-Thy1.1 construct or control plasmids. Cells were expanded 
for 4 additional days in the presence of CD3 and CD28-coated beads and IL-2 prior to 
sorting Thy1.1-positive GFP
+
 Treg. Transduced cells showing highly similar FOXP3 
expression were used for further analysis (Supplementary Fig. 15a). In contrast to control-
transduced Treg, SATB1 over-expressing FOXP3
+
 Treg cells lost their suppressive function 
and gained TH1 (IFN-) and TH2 (IL-5) effector cytokine expression (Supplementary Fig. 
15b-e and Fig. 9b) supporting a reprogramming of Treg cells into Teffector in the presence of 
high levels of SATB1 observed in human Treg.  
To assess in vivo suppressor capacity of Treg overexpressing SATB1 we transferred 




 T cells isolated from normal mice into 
RAG2
-/-




 T cells alone led to the 
development of colitis (Fig. 9c-e). As expected, RAG2
-/-





 T cells and control vector-transduced Treg did not lose weight (Fig. 9c-e). 
In agreement with the reduced suppressor activity observed in vitro, SATB1-
18 
overexpressing Treg showed an impairment in suppressor function, reflected in weight loss 




 T cells (Fig. 
9c-e). We observed a significant expansion in the number of Tconv in mice receiving either 
no Treg or SATB1-overexpressing Treg in spleen, mesenteric and peripheral lymph nodes 
(Fig. 9f), while the number of cells that maintained FOXP3 expression in spleen, 
mesenteric and peripheral lymph nodes was equal in mice receiving control vector-
transduced or SATB1-overexpressing Treg (Fig. 9g). Thus, FOXP3
+
 Treg cells in the 
presence of SATB1 show lower suppressor function with a concomitant gain of Teffector 
programs in vivo and in vitro suggesting that downregulation of SATB1 in Treg is necessary 




In Treg numerous mechanisms have been implicated in their suppressive function 
upon contact to other immune effector cells, amongst them CTLA4 expression, secretion of 
inhibitory cytokines, target cell lysis or impaired APC activation
1
. At the same time 
intrinsic inhibition of Teffector function mainly by FOXP3-induced mechanisms - as 
exemplified by the induction of the transcriptional repressor Eos
15
 - seems to be necessary 
for Treg to exert suppressive function. In this report we identified the repression of SATB1 
in Treg to be required for suppressive function and inhibition of effector differentiation of 
these cells. Inhibition of SATB1 in Treg is conserved between man and mice. In scurfy mice 
immunopathology is associated with a strong upregulation of SATB1 and downstream 
effector cytokines in the Treg compartment suggesting that the induction of Teffector function 
by Treg contributes to the immunopathology of these mice. A defining difference in SATB1 
regulation in Treg compared to a Tconv was the profound lack of upregulation of SATB1 
following stimulation. As up-regulation of SATB1 is required for the induction of Teffector 
cytokines in Tconv this suggests that FOXP3-mediated suppression of SATB1 plays an 
important role in inhibiting cytokine production within a Treg. In support of this, the ectopic 
expression of high levels of SATB1 in Treg led to the induction of Teffector cytokines and loss 
of suppressive function despite the expression of FOXP3 in vitro and in vivo. 
Mechanistically, SATB1 expression is controlled directly by FOXP3-mediated 
transcriptional repression, histone modifications as well as the induction of at least 5 
miRNAs binding to the 3’UTR of SATB1. Together these findings establish that 
continuous active repression of central mechanisms involved in Teffector programs provided 
by SATB1 is necessary for Treg to exert their suppressive function.        
20 
Thus a major finding of our study is that Treg not only depend on the induction of 
FOXP3-mediated genes associated with suppressive function but also on the specific 
repression of molecules such as SATB1 to prevent Teffector function. SATB1 is not only a 
critical factor in early T-cell development
31
, but also plays an important role in Teffector 
differentiation
34, 45
. SATB1 expression at low levels seems to be necessary to retain 
functional T-cell integrity not only in Tconv but also in Treg as complete SATB1 KO have 
basically no T cells in the periphery
31, 46
. However, in the peripherally under stimulating 
conditions, the TCR induced upregulation of SATB1 observed in Tconv which is important 
for their differentiation and cytokine secretion is blocked in Treg by both direct FOXP3 
binding and indirect mechanisms including miRNA dependent regulation and repressive 
histone modifications. SATB1 has been shown to delineate specific epigenetic 
modifications at target gene loci thereby reprogramming chromatin organization and 
transcriptional programs
33, 46, 47
. Although many reports suggest SATB1 mainly exerts 
repressor activity
48
, SATB1 clearly can function as an activator of transcription
49
, 
particularly in Thelper cell differentiation
34, 45
. Similar to our finding in polyclonal naïve 
human T cells, SATB1 has also been shown to be induced after activation of a T helper 
type 2 clone
34
. In this context, SATB1 can interact with multiple binding sites across the T 
helper type 2 cytokine loci to create a highly looped locus conformation bringing different 
TH2 cytokine loci in close proximity, an apparent pre-requisite for the induction of genes 
encoding TH2 cytokines. The induction of TH1 as well as TH17 cytokines in polyclonal 
Treg strongly suggests that SATB1 may play a similar role in other Teffector populations. 




 T cells under polarizing conditions (TH1, 
TH2, TH17) leads to significantly reduced effector cytokine expression in these cells 
21 
(Beyer, Schultze, unpublished data). While FOXP3 clearly dictates the repression of 
SATB1 in Treg thereby preventing Teffector function, we have no evidence so far for an 
inverse control of FOXP3 by SATB1 in Tconv, which together favors a model with Teffector 
programs continually and actively overruled by FOXP3-mediated transcriptional repression 
within a Treg. 
Further evidence for such a model comes from studies elucidating the effect of the 
transcriptional repressor Eos, which is expressed at elevated levels in Treg
15
. Eos directly 
interacts with FOXP3 to specifically induce chromatin modifications that result in gene 
silencing, while genes induced by FOXP3 were not affected by Eos expression and 
function. Interestingly, loss of Eos function abrogated suppressive Treg function but only 
partially endowed Treg with Teffector functions consistent with the normal repression of 
Teffector differentiation within a Treg. Similarly, loss of Runx1-CBF heterodimers, another 
component of the FOXP3 containing multi-protein complex, by conditional knockout in 
Treg leads to reduction of FOXP3 expression, loss of suppressor function and gain of IL-4 
expression by Treg
50, 51
. FOXP3 as well as Eos and Runx1-CBF heterodimers have been 
shown to directly repress certain effector cytokines such as IFN or IL-4 suggesting Treg 
may use multiple mechanisms to suppress Teffector programs
15, 20, 50
. Nevertheless, the 
ectopic expression of SATB1 in Treg by lentiviral gene transfer at levels comparable with 
activated Tconv was sufficient to induce effector cytokines suggesting that high levels of 
SATB1 can overcome FOXP3 repression of downstream targets. This might be similarly 
true in activated Tconv that can express lower levels of FOXP3 temporarily during early 
activation phases.  
22 
Recently the FOXO transcription factors Foxo1 and Foxo3 have also been 
implicated in the inhibition of Teffector function in Treg
16
. Interestingly, lack of Foxo1 and 
Foxo3 in Treg is sufficient to induce TH1 and TH17 effector cytokines but not TH2 
cytokines whereas SATB1 seems to have a more profound effect on TH2 cytokines under 
certain conditions
34, 45





 double KO Treg suggests that SATB1 is not a direct target of 
Foxo1 and Foxo3 indicating that repression of the different Teffector cytokine loci in Treg may 
occur either by separate or multiple mechanisms. Together these findings point to a 
hierarchy of repressive mechanisms ensuring suppression of Teffector function in Treg.             
We could establish that epigenetic regulation by altered histone modifications 
contributes to the lower expression of SATB1 in Treg. We observed less permissive and 
more repressive histone modifications in human as well as murine Treg suggesting that 
epigenetic regulation of the SATB1 locus represents an additional layer of regulation 
present to preserve low levels of SATB1 expression in Treg.      
Another finding of our study was the control of SATB1 by at least 5 miRNAs that 
are all highly upregulated in FOXP3
+
 Treg. These findings are in line with recently 
suggested concepts of feed forward control of gene transcription by transcriptional 
repressors and miRNAs that are induced by the same transcriptional repressor
52
. At least 3 
of these miRNA are direct targets of FOXP3 as reported previously for miR-155 and miR-
21
29, 42-44
. While silencing single miRNAs was not sufficient to significantly change 
SATB1 protein expression complete loss of miRNAs in Treg by conditional KO of DICER 
in Treg clearly increased SATB1 expression in these Treg. Although this experiment cannot 
rule out the possibility of indirect mechanisms leading to elevated SATB1 expression 
23 
exerted by the complete loss of miRNAs in these cells, the presence of conserved and 
functionally important binding sites of these highly upregulated miRNAs in the 3’UTR of 
the SATB1 mRNA strongly suggests that miRNA control plays an important role in 
repression of SATB1 in Treg.  
In conclusion, we have established FOXP3-mediated repression of SATB1 as a 
prerequisite for suppressive function and inhibition of Teffector mechanisms in Treg. This was 
not only mediated by direct FOXP3-mediated transcriptional repression but also by 
epigenetic modifications and the induction of several miRNAs (Supplementary Fig. 17). 
Together with other previous reports our findings support a model of continuously active 
regulatory networks shaping the overall function of T cells in the periphery as an alternative 
to terminal differentiation. An active and continuous blockade of Teffector function instead of 
terminal Treg differentiation allows T cells a higher degree of functional plasticity e.g. under 
inflammatory conditions where Treg can gain effector function once FOXP3 is switched 
off
27, 53-55
. Therapeutic manipulation of these regulatory networks may provide new 
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Figure Legends  
 
Figure 1. FOXP3-dependent repression of SATB1 expression in human regulatory 
T cells. 
(a) Microarray analysis of SATB1 mRNA expression in Tconv and Treg (rest=resting, 
act=activated, TGF=TGF treated, exp=expanded). (b) Relative SATB1 mRNA 
expression in freshly isolated Treg and Tconv assessed by qRT-PCR (mean±s.d., 
n=5; * p<0.05). (c) Western blotting of SATB1 in freshly isolated Treg and Tconv 
(representative donor (left), relative expression (right; n=6, mean±s.d.; * p<0.05). 
(d) Flow cytometric analysis of SATB1 expression in freshly isolated Treg and Tconv 
(left: representative donor; right: mean±s.d., n=11; * p<0.05) (e) Flow cytometry of 
SATB1 after stimulation of Treg and Tconv for 2 days normalized to resting Tconv (left: 
representative donor; right: mean±s.d., n=5; * p<0.05). (f) qRT-PCR for SATB1 in 
iTreg on day 5 (mean±s.d.; n=6; * p<0.05; Tunst=unstimulated; Tstim=stimulated; 
iTreg=induced Treg). (g) Flow cytometry of SATB1 in iTreg on day 5 (left: 
representative experiment; right: n=3, mean±s.d.; * p<0.05)). (h) Bead assay for IL-
4 and IFN- secretion in the supernatants of Tunst, Tstim, and iTreg (mean±s.d.; * 
p<0.05). (i) qRT-PCR for FOXP3 (left) and SATB1 (right) in Tconv lentivirally 
transduced with FOXP3 rested for 3 days (mean±s.d., n=5; * p<0.05). (j) qRT-PCR 
analysis of IL-5 (left) and IFN- (right) expression in Tconv lentivirally transduced 
with FOXP3 rested for 3 days (mean±s.d., n=5, * p<0.05).  
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Figure 2. Rescue of SATB1 expression after silencing of FOXP3 in Treg.  
Human Treg were either transfected with control siRNA or FOXP3-specific siRNA 
and assessed 48 hours post knockdown. (a) Flow cytometric analysis of 
intracellular FOXP3 expression in Treg post FOXP3 knockdown compared to control 
siRNA transfected Treg (left: representative donor; right: mean±s.d., n=6; * p<0.05). 
(b) Suppressive function in vitro of control or FOXP3 siRNA treated Treg cultured for 
4 d together with CFSE-labeled allogeneic CD4+ T cells at a 1:1 ratio; after 
stimulation of cultures, CFSE dilution was assessed by flow cytometry. (c) qRT-
PCR for SATB1 (mean±s.d., n=6; * p<0.05) in human Treg after silencong of 
FOXP3. Treg were transfected and cultivated for 48 hours without stimulation or in 
the presence of CD3 and IL-2 or CD3 and CD28. (d) qRT-PCR for IL-5 and IFN- 
(n=4, mean±s.d.; * p<0.05) in siRNA-treated Treg stimulated for 48 hours in the 
presence CD3 and IL-2. (e) Bead assay for IL-4 and IFN- (mean±s.d.; * p<0.05) in 
the supernatant of siRNA-treated Treg stimulated for 48 hours in the presence of 
CD3 and IL-2. (f) qRT-PCR for IL-5 and IFN- in Treg transfected with FOXP3-
specific siRNA alone or FOXP3- and SATB1-specific siRNAs followed by 
stimulation with CD3 and CD28 for 48 hours (n=4, mean±s.d., one-way ANOVA 
with LSD; * p<0.05).  
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Figure 3. FOXP3-dependent repression of SATB1 expression in murine regulatory 
T cells. 
(a) Flow cytometric analysis of SATB1 in freshly isolated Treg and Tconv from spleen 
from male DEREG mice (left: representative mouse; right: mean±s.d., n=3; * 
p<0.05). MFI values are presented for Treg and Tconv respectively. (b) Western blot 
analysis of SATB1 protein expression in murine Treg and Tconv. (c) Z-projection of 
immunofluorescence for SATB1 (red) and GFP (green) protein expression in 
thymocytes from male DEREG mice counterstained with DAPI (blue). White arrow 
depicts a Treg. (d) qRT-PCR of SATB1 in freshly sorted CD4+GFP+ (Treg) and 
CD4+GFP- (Tconv) T cells (♂ DEREG mice; ♂ FOXP3-deficient DEREG x scurfy 
mice). Data are representative of two experiments (mean ± s.d. of three biological 
replicates; * p<0.05). (e) qRT-PCR of IL-6 and IFN- mRNA production by Treg 
derived from male DEREG or DEREG x scurfy mice. (mean±s.d.; * p<0.05; n.d. = 
not detectable). (f) Confocal immunofluorescence for SATB1 (red) and FOXP3 
(green) in freshly sorted thymic Treg from female DEREG mice heterozygous for the 
scurfy mutation counterstained with DAPI (blue). FOXP3 competent: 
CD4+GFP+FOXP3+,(FOXP3wt Treg) or FOXP3 incompetent: CD4+GFP+FOXP3-  
(FOXP3sf Treg). (g) Flow cytometry of SATB1 in freshly isolated thymic single 
positive FOXP3+ (left, dark grey) and FOXP3- (right, black) GFP+ Treg from female 
DEREG mice heterozygous for the scurfy mutation; one representative experiment 
(left); mean±s.d. (right, n=2). Isotype control shown as solid line. 
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Figure 4. Direct suppression of SATB1 mRNA transcription by FOXP3.  
(a) FOXP3 ChIP tiling array data from human expanded cord-blood Treg assessed 
with a FOXP3 antibody and hybridized to either Affymetrix promoter or Affymetrix 
tiling arrays. Data were analyzed with MAT and overlayed to the SATB1 locus to 
identify binding regions (1-13, p<10-5 and FDR<0.5%). (b) Schematic 
representation of FOXP3 binding regions (BR) at the human genomic SATB1 locus 
identified by in silico prediction within the indentified regions. (c) ChIP-qPCR for 
FOXP3 binding at the SATB1 locus in human expanded cord-blood Treg. Input DNA 
and precipitated DNA were quantified by real-time PCR; the same chromatin was 
used for control ChIP experiments with immunoglobulin G–coupled Dynabeads. 
Enrichment over input DNA was normalized to control IgG (mean±s.d.; * p<0.05; 
n=3). (d) Luciferase reporter assay comparing wildtype to mutated FOXP3 binding 
regions (mean±s.d.; * p<0.05; n=3). FOXP3 binding was assessed by transfecting 
a reporter construct containing the potential FOXP3 binding region in cells 
expressing FOXP3 comparison to an empty control. Constructs with mutated 
motifs were used to demonstrate specificity. (e) Determination of the KD-values of 
FOXP3 binding to FOXP3 binding motifs in BR9 and BR10 at the SATB1 locus by 
filter retention analysis.  
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Figure 5. SATB1 expression in Treg reprograms Treg into effector T cells.  
(a) Analysis of suppressive function of human Treg lentivirally transduced with 
SATB1 (blue) or control vector (DsRED, red) cultured for 4 d together with CFSE-
labeled allogeneic PBMC at a 1:1 ratio in vitro; after stimulation of cultures, CFSE 
dilution of human CD8+ T cells was assessed by flow cytometry. Left: 
representative experiment; right: mean±s.d., n=3; * p<0.05. (b) Bead assay for IL-4 
and IFN- secretion of human Treg lentivirally transduced with SATB1 or control 
vector assessed 4 and 16 hours after stimulation with CD3/CD28-coated beads 
(mean±s.d.; * p<0.05). qRT-PCR analysis of (c) IL-5, (d) IFN-, and (e) IL-17A 
expression in Tconv activated for 16 hrs with CD3/CD28 coated beads (grey) as well 
as human Treg lentivirally transduced with SATB1 (blue) or control vector (DsRED, 
red) (mean±s.d., n=3, * p<0.05). 
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Figure 6. Transcriptional Teffector programs are induced in SATB1 expressing Treg 
(a) Up- and down-regulated genes in Treg lentivirally transduced with SATB1 or 
control vector after 16 hours stimulation with CD3/CD28-coated beads. Data were 
z-score normalized. (b) Cross annotation analysis using 4 classes: Genes 
associated with Tconv but not Treg cells (yellow), with T cell activation (green), 
common T-cell genes (orange), and SATB1-induced genes (black). (c) 
Visualization of gene expression levels of genes previously associated with TH1, 
TH2, or TH17 differentiation; data were z-score normalized. p-values for TH 
associated genes determined by ² test in comparison to the complete data set (= 
TH specific gene enrichment) were p = 3.236e-06 (TH1), p = 9.017e-15 (TH2), 
resp. p = 1.157e-06 (TH17). (d) Changes in genes associated with the human Treg 
signature in Treg lentivirally transduced with SATB1 in comparison to control vector 
transduced Treg. The mean log2 fold-changes of the comparison Treg to Tconv (red 
dots) and SATB1 to control-transduced Treg (blue dots) were plotted and both 
comparisons were ranked by fold change in the Treg vs. Tconv comparison. 
44 
Figure 7. Epigenetic regulation of SATB1 in Treg.  
(a) DNA methylation of the predicted CpG-islands in the genomic region of SATB1 
in Treg and Tconv. (b) Histone ChIP sequencing data from human expanded Treg and 
Tconv for the permissive histone modifications H3K4me3 and H4Ac and the 
repressive histone modification H3K27me3. Data were analyzed with MACS and 
overlayed to the SATB1 locus histone marks (-10log10 p>100 and FDR<0.5%). (c) 
Confirmation of histone marks for H3K4me3, H4Ac, and H3K27me3 in human 
expanded Treg and Tconv by ChIP-qPCR. Quantitative PCR was performed using 
primer sets corresponding to the marked regions and histone antibody or control 
IgG precipitated chromatin isolated from Treg and Tconv. Relative enrichment of 
FOXP3 Chip over input normalized to IgG were calculated. (mean±s.d.; * p<0.05; 
n=3) Primer sequences are listed in table S10.  
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Figure 8. SATB1 is repressed by miRNA in Treg.  
(a) Representation of the human genomic SATB1 3′ UTR and the conserved 
miRNA binding sites. (b) qPCR for miR-155, miR-21, miR-7, miR-34a, and miR-
18a in human Treg (mean±s.d., n=5; * p<0.05). (c) Correlation of miRNA expression 
with SATB1 mRNA expression is plotted against miRNA fold change (Treg vs. Tconv) 
for all 735 miRNA assessed by microarrays. Highlighted are miR-155, miR-21, 
miR-7, miR-34a, and miR-18a. (d) FOXP3 ChIP tiling array data for miR-155, miR-
21, and miR-7. (e) Confirmation of FOXP3 binding to the miR-155 and miR-21 loci 
by ChIP-qPCR. Quantitative PCR was performed using primer sets corresponding 
to the marked regions and FOXP3 antibody or control IgG precipitated chromatin 
isolated from Treg. Relative enrichment of FOXP3 Chip over input normalized to IgG 
were calculated. The AFM locus was used as a negative control. Primer 
sequences are listed in table S5. (f) Luciferase reporter assays comparing the WT 
SATB1 3′ UTR to a version containing mutated miRNA-binding sites (mean±s.d.; * 
p<0.05, n=3). Functional miRNA binding was assessed by transfecting a reporter 
construct containing the WT SATB1 3′ UTR in cells transfected with miRNA 
mimics. Constructs with mutated motifs were used to demonstrate specificity.  (h) 
Western blot of SATB1 in sorted Treg from mice with a Treg-specific complete 
DICER loss (DICERfl/fl) in comparison to DICERwt/fl Treg. 
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Figure 9. Ectopic expression of SATB1 in Treg results in reduced suppressive 
function in vivo.   
(a) Analysis of suppressive function of murine expanded Treg lentivirally transduced 
with SATB1 (blue) or control vector (red) cultured for 4 d together with eFluor 670-
labeled CD4+ T cells at a the indicated ratio in vitro; after stimulation of cultures, 
eFluor 670 dilution of CD4+ T cells was assessed by flow cytometry. Left: 
representative experiment; right: mean±s.e.m. Data are representative of two 
independent experiments (mean and s.e.m. of triplicate cultures). (b) qRT-PCR 
analysis of IL-5 and IFN- in murine Treg lentivirally transduced with SATB1 (blue) 
or control vector (red) (mean±s.d., n=3, * p<0.05). (c) Hematoxylin and eosin 
staining of colon sections. Colons from mice that received naïve CD4+CD45RBhigh 
T cells only or together with SATB1-overexpressing Treg displayed infiltrates of 
inflammatory cells. In colons from mice that received naïve CD4+CD45RBhigh T 
cells and control Treg no inflammatory changes were evident. (d) Histology scores 
of sections of the colon at 8 weeks after cell transfer. (e) Body weight of RAG2-/- 
recipients of naïve CD4+CD45RBhigh T cells transferred alone or together with 
control- or SATB1-transduced Treg, presented relative to initial body weight. Data 
are pooled from two independent experiments (average and s.d. of four to five 
recipient mice). (f) Recovery of Tconv cells from spleens mesenteric and peripheral 





















Supplementary Fig. 1. Layout of microarray experiments  
Human CD4+ T cells resp. CD4+CD25- Tconv, were assessed either directly after 
isolation or after up to 26 hours of cell culture without further stimulation (resting 
Tconv), after culture in the presence of TGF- for 18 to 26 hours (TGF- Tconv), or 
2 
after activation for 8 to 24 hours by various stimuli (Tconv activated) including also 
CD4+ T cells stimulated in the presence of inhibitory signals including IL-10, 
prostaglandin-E2 (PGE2), PD1, or CTLA-4 (see also Supplementary Table 1). 
Human Treg were analyzed either directly after isolation or after culture for up to 6 
hours without further stimulation (resting Treg), after culture in the presence of 




Supplementary Fig. 2. Expression of Treg-cell genes in FOXP3-transduced Tconv. 
To assess whether FOXP3 overexpression induces typical Treg-cell associated 
genes, we transduced Tconv with a lentivirus containing the full length human FOXP3 
cDNA. Treg-cells gene signatures were assessed by (a) whole genome 
4 
transcriptome analysis and subsequent visualization of expression of the Treg-cell 
gene signature and (b) qRT-PCR of a set of known Treg-cell marker genes 





Supplementary Fig. 3. Treg-cell associated gene expression in FOXP3-silenced 
human Treg. 
To assess whether silencing of FOXP3 reverses the phenotype of Treg, we isolated 
Treg and performed siRNA-mediated knockdown of FOXP3 and analyzed mRNA 






Supplementary Fig. 4. FOXP3 and SATB1 mRNA expression in FOXP3/SATB1-
silenced human Treg. 
To assess whether SATB1 is responsible for the increased production of T-helper 
cytokines, we isolated Treg and performed siRNA-mediated knockdown of FOXP3 or 
FOXP3 and SATB1 and analyzed SATB1 mRNA expression after stimulation for 48 
hours with CD3 and CD28. qRT-PCR for (a) FOXP3, and (b) SATB1 in nTreg 
transfected with FOXP3-specific siRNA alone or FOXP3- and SATB1-specific 
siRNAs followed by stimulation with CD3 and CD28 (mean±s.d., one-way ANOVA 




Supplementary Fig. 5. Experimental protocol for combined silencing of SATB1 and FOXP3 in expanded human Treg with 
artificial miRNA. 
FACS-sorted human CD4+CD25highCD127lowCD45RA+ Treg were expanded for 14 days with CD3 and CD28-coated beads in 
the presence of IL-2. After this initial expansion, Treg were lentivirally transduced with miRNA against FOXP3, FOXP3 and 
SATB1 or control plasmids containing EmGFP, expanded for 3 additional days in the presence of CD3 and CD28-coated 
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beads and IL-2. Cells sorted on EmGFP-positivity using a FACS Aria III sorter (BD Biosciences) showing highly similar 
EmGFP expression were used for further analysis. Relative (a) FOXP3, (b) SATB1, (c) IL-5, and IFN- mRNA expression in 






Supplementary Fig. 6. Assessment of induction of Treg-cell associated genes in 
human CD4+ Tconv after silencing of SATB1. 
(a) To assess whether silencing of SATB1 induces FOXP3, we isolated naïve Tconv, 
performed siRNA-mediated knockdown of SATB1, rested them (resting), stimulated 
them with CD3/CD28 coated beads (stimulated) or cultivated them in the presence 
of CD3/CD28 coated beads, TGF- and IL-2 to induce iTreg (iTreg). We analyzed 
FOXP3 expression by flow cytometry (mean±s.d., n=4; * p<0.05). (b) To assess 
whether silencing of SATB1 induces other genes associated with the Treg-cell 
phenotype, we isolated Tconv, performed siRNA-mediated knockdown of SATB1, 
stimulated them with CD3/CD28 coated beads and analyzed mRNA expression for 





Supplementary Fig. 7. Array and ChIP-qPCR results for FOXP3 binding to SATB1 
and known FOXP3 target genes. 
(a) FOXP3 binds to the promoter region of the human SATB1 locus. FOXP3 ChIP-
on-chip experiments and data analysis using MAT were previously described1. Each 
bar represents the signal intensity of an individual oligonucleotide probe on 
Affymetrix Human Promoter 1.0 (upper panel) or Human Tiling 2.0R Array (lower 
panel). (b) FOXP3 binds to the human CTLA4 locus. (c) FOXP3 binds to the human 
IL7R locus. (e) No FOXP3 binding to the human AFM locus. (e) FOXP3 binds to the 
human PDE3B locus. (f) Confirmation of FOXP3 binding by ChIP-qPCR. 
Quantitative PCR was performed using primer sets corresponding to the marked 
regions and FOXP3 antibody or control IgG precipitated chromatin isolated from Treg 
cells. Relative enrichment of FOXP3 Chip over input normalized to IgG were 
calculated. The AFM locus or intron 10 of PDE3B was used as a negative control. 




Supplementary Fig. 8. Experimental protocol for overexpression of SATB1 in primary human Treg. 
MACS-isolated human CD4+CD25high Treg or CD4+CD25- Tconv were stimulated for 24 hours with CD3 and CD28-coated beads 
in the presence of IL-2. After this initial stimulation, Treg were lentivirally transduced with pELNS DsRED 2A SATB1 or control 
plasmids containing DsRED expressed at a ratio of 1:1 to the transgene2, expanded for 6 days in the presence of CD3 and 
13 
CD28-coated beads and IL-2. Cells sorted for DsRED-positivity using a MoFlo sorter (DakoCytomation) showing highly similar 
DsRED expression were used for further analysis. Relative (a) FOXP3 and (b) SATB1 mRNA expression in DsRED- rSATB1-
transduced Treg was assessed by qRT-PCR and compared with freshly isolated Tconv (mean±s.d., n=3; * p<0.05). (c) Relative 
SATB1 protein expression in DsRED- SATB1-transduced Treg was assessed by flow cytometry and compared with freshly 





Supplementary Fig. 9. Human Tconv transduced with SATB1 show no suppressive 
function. 
PBCM were cultured in the presence of CD3 beads together with human Tconv 
lentivirally transduced with SATB1 (light blue) or control vector (DsRED, light red) at 
a 1:1 ratio. Analysis of proliferation of human CD8+ T cells as determined by flow 





Supplementary Fig. 10. DNA methylation of the CpG island of the FOXP3 
locus in freshly isolated Treg and Tconv. 
As a positive control, DNA methylation of the described CpG-islands in the human 




Supplementary Fig. 11. Histone methylation at the human SATB1 gene locus. 
Presence of H3K4me, H3K27me3, and H4Ac at the SATB1 locus in human 
expanded Tconv and Treg. Each bar represents the cumulative frequency of matching 




Supplementary Fig. 12. Histone methylation at the murine SATB1 gene locus. 
Recently published data on genome-wide histone methylation were reanalyzed for 
SATB1 expression and histone methylation maps in murine naive T cells, Teffector 
(TH1, TH2, resp. TH17), iTreg and nTreg4. (a) expression of SATB1 as assessed by 
microarray analysis. (b) and (c) ChIP-sequencing data were re-analyzed over the 
SATB1 locus. Trimethylation of H3K4 (b, left) is associated with gene activation, 
whereas di- and trimethylation of H3K27 (b, right) are associated with gene 
repression. Low to absent trimethylation of H3K27 was detected in the Teffector 
subsets analyzed, while Treg showed this repressive histone mark. In contrast, 
Teffector showed high levels of H3K4 trimethylation while in Treg lower trimethylation of 
H3K4 could be observed. b, cumulative data for H3K4 (left) and H3K27 (right) in 
Tnaive, TH1, TH2, TH17. iTreg, and nTreg (n.d. = not detectable). c, analysis of 




Supplementary Fig. 13. Results for FOXP3 binding to miRNA genes. 
FOXP3 binds in close proximity of (a) the human miR-155, (b) the human miR-21, 
and (c) the two human miR-7 loci. FOXP3 ChIP-on-chip experiments and data 
analysis using MAT were previously described1. Each bar represents the signal 
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intensity of an individual oligonucleotide probe on Affymetrix Human Promoter 1.0 





Supplementary Fig. 14. Expression of miRNAs in FOXP3-overexpressing Tconv and 
Treg after silencing of FOXP3. 
To assess whether FOXP3 is responsible for the increased expression of miR-155, 
miR-21a, miR-7. miR-34a, and miR-18a, (a) we transduced Tconv with a lentivirus 
containing the full length human FOXP3 cDNA and analyzed miRNA expression or 
(b) isolated Treg and performed siRNA-mediated knockdown of FOXP3 and 
analyzed miRNA expression after stimulation for 48 hours with CD3 and IL-2 (mean 





Supplementary Fig. 15. SATB1 expression after inhibition of miRNA in Treg. 
(a) MACS-purified human natural Treg were transfected with either a control or miR-
155 inhibitor and regulation of SATB1 mRNA expression was assessed 48 hours 
post knockdown by qRT-PCR (mean +/- s.d., n=5, * p<0.05) in unstimulated or CD3 
and IL-2 stimulated Treg. (b) Western blot analysis of SATB1 protein expression in 
sorted freshly isolated Treg from mice with a Treg-specific complete DICER loss 




Supplementary Fig.16. Experimental protocol for overexpression of SATB1 in murine human Treg. 
FACS sorted murine CD4+GFP+ Treg from DEREG mice were expanded for 10-14 days with CD3/CD28-coated beads in the 
presence of IL-2. After this expansion period, Treg were transduced with  pLVTHM-SATB1-IRES-Thy1.1 or control lentivirus 
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and cultivated in the presence of CD3/CD28 coated beads and IL-2 for 3 to 4 days. SATB1-Thy1.1-transduced, control-
transduced or non-transduced expanded Treg were sorted on GFP and Thy1.1 expression or GFP expression alone on a 
FACS Aria III (BD). (a) FOXP3 protein expression in SATB1-Thy1.1-transduced, control-transduced or non-transduced 
expanded Treg was assessed by flow cytometry. (b) SATB1 and (c) IL-5, and IFN- mRNA expression in SATB1-Thy1.1-
transduced Thy1.1-positive, SATB1-Thy1.1-transduced Thy1.1-negative, control-transduced or non-transduced expanded Treg 
was assessed by qRT-PCR (mean±s.d., n=3; * p<0.05). (d) Thy1.1 protein expression before and after sorting of SATB1-
Thy1.1-transduced Treg into SATB1-Thy1.1-transduced Thy1.1-positive and SATB1-Thy1.1-transduced Thy1.1-negative Treg 
was assessed by flow cytometry. (e) Comparison of suppressive function of SATB1-Thy1.1-transduced Thy1.1-positive, 





Supplementary Fig. 17. Model for the mode of action of FOXP3. 
A, B, Model for the FOXP3- and miRNA-mediated SATB1-dependent remodelling of the respective genomic loci for the 






C57BL/6 (B6) mice were purchased from the Jackson Laboratory. RAG2
-/-
, DEREG, 
scurfy and DEREG x scurfy mice were previously described
5-8
. The male DEREG x scurfy 
mice were indistinguishable from scurfy mice in regard to the immunological and clinical 
manifestations of autoimmunity, while female DEREG mice heterozygous for the FOXP3 
mutation were symptom free. Mice were housed under specific pathogen-free conditions at 
the TWINCORE, Centre for Experimental and Clinical Infection Research or at the LIMES 
Institute, University of Bonn and used in accordance with the German legislation governing 
animal studies following The Principles of Laboratory Animal Care (NIH publication No. 
85-23, revised in 1996). 
FoxP3-GFP-hCre BAC Dicer
lox/lox
 mice and FoxP3-GFP-hCre BAC Dicer
lox/lox
 
ROSA26R-loxP-Stop-loxP-YFP mice have been previously described
9
. Mice were housed 
and bred under specific pathogen-free conditions at the UCSF Animal Barrier Facility of the 
University of California, San Francisco. All animal experiments were approved by the 
Institutional Animal Care and Use Committee of the University of California, San 
Francisco. 
 
Antibodies and FACS analysis. 
Fluorescent-dye-conjugated antibodies were purchased from Becton Dickinson, 
BioLegend, or eBioscience. Alexa 647-conjugated mouse anti-human SATB1 monoclonal 
antibody (clone 14) cross-reactive to murine SATB1 was prepared by R. Balderas (BD 
Biosciences). FACS data were acquired on a FACSCanto II and LSR II flow cytometer 
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(Becton Dickinson) and analyzed using FlowJo software package (Tri-Star). Intracellular 
staining of human and murine FOXP3 and SATB1 was conducted using either the human or 
mouse FOXP3 Regulatory T-cell Staining Kit (BioLegend) with the addition of FcR-
blocking reagents (CD16/CD32 or human IgG) 15 min before intranuclear staining. 
 
Purification and sorting of human Treg. 
Human Treg and Teffector were purified from whole blood of healthy human donors in 
compliance with institutional review board (IRB) protocols by negative selection using 
CD4-RosetteSep (Stem Cell), followed by positive-selection using CD25-specific MACS 
beads (Miltenyi Biotech) or sorting on a FACSDiVa or Aria III cell sorter (Becton 
Dickinson) after incubating cells with combinations of fluorochrome-labeled monoclonal 
antibodies to CD4, CD25, and CD127. For experiments with non-sorted cells, only samples 
with >95% Treg were used.  
 





 Treg were purified from thymus, spleen, or peripheral lymph nodes by 
sorting on a MoFlo high performance cytometer (Beckman Coulter) or FACSDiVA or Aria 
III cell sorter for CD3 and CD4 stained GFP
+
 cells directly or following enrichment of CD4
+
 
T cells using the CD4 negative isolation kit (Invitrogen or Miltenyi Biotech). 
 
Generation of iTreg. 
Human CD4
+
 lymphocytes were purified from whole blood of healthy human donors 
by negative selection using CD4-RosetteSep (Stem Cell). After negative selection with 
CD25-specific MACS beads (Miltenyi Biotech), conventional CD4
+
 lymphocytes were 
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incubated with CD45RA-specific MACS beads (Miltenyi Biotech). Naïve conventional T 
cells were obtained by passing the cell mixture over LS magnetic separation columns in a 






 T cells. Naive Treg-
depleted CD4
+




) were stimulated in serum-free Aim-V/X-Cell 
(50%/50% V/V) medium with 5 x 10
4
 magnetic beads coated with 5% CD3 (OKT3, Ortho 
Biotech), 12% CD28 (9.3), and 83% anti-MHC-I (W6/32) monoclonal antibody well
-1
 and 
TGF1 (R&D systems) 5 ng ml-1 for a period of 7 days in the absence of IL-2. The 
described composition of beads was optimized for the induction of iTreg cells. 
 
qRT–PCR on human samples. 
Total RNA extracted using TRIZOL (Invitrogen) from Tconv, Treg, or iTreg was used to 
generate cDNA along with the Transcriptor First Strand cDNA synthesis kit (Roche 
Diagnostics). qRT–PCR was performed using the LightCycler Taqman master kit and the 
Universal Probe Library assay specific for SATB1, FOXP3, IL-5, IFN-, Treg-cell specific 
genes and beta-2 microglobulin (B2M; Roche Diagnostics) on a LightCycler 480 II (Roche 
Diagnostics). For each experiment at least two technical replicates were performed. Results 
were normalized to B2M expression. PCR primer sequences are listed in table S3. 
 
Western blot analysis. 





 Treg were prepared as previously described
10
 followed by western 




Whole-genome gene expression in human cells. 
All RNA was extracted using TRIZOL (Invitrogen) and purified in our laboratory 
using standard methods. Sample amplification, labelling and hybridization on Illumina WG6 
Sentrix BeadChips V1 were performed for all arrays shown in Fig. 1a according to the 
manufacturer’s instructions (Illumina) using an Illumina BeadStation. All data analyses were 
performed by using Bioconductor for the statistical software R (http://www.r-project.org). 
Expression values were normalized and summarized by using the IlluminaGUI package
11
. 
From the resulting data sets we extracted a list of genes with a significant different 
expression in Treg compared to Tconv. Microarray data can be accessed under GSE15390. 
For SATB1-transduced Treg as well as FOXP3-transduced Tconv Illumina WG6 Sentrix 
BeadChips V3 were used according to the manufacturer’s instructions (Illumina) using an 
Illumina BeadStation All data analyses were performed by using Bioconductor for the 
statistical software R (http://www.r-project.org). Expression values were normalized and 
summarized by using the IlluminaGUI package
11
. From the resulting data sets we extracted a 
list of genes with a significant different expression in SATB1-transduced Treg compared to 















 T cells activated for 5 
days with CD3/CD28-coated beads, as well as unstimulated naive T cells to define Tconv-
dependent genes (differentially expressed between Tconv and Treg), T-cell activation 
dependent genes (differentially expressed between activated and unstimulated naive T cells), 
and common T-cell genes (changed in the same direction in both comparisons). For 
enrichment analysis of TH gene sets, the expression dataset was filtered for expressed 
probes and significance of enrichment was calculated using χ² statistic implemented in R. 
For verification of SATB1, FOXP3, IL-5, IFN-, and IL17A mRNA expression in these 
30 
samples by qRT-PCR, total RNA was extracted using TRIZOL. First strand complementary 
DNA was synthesized with the Transcriptor First Strand cDNA synthesis kit (Roche 
Diagnostics). qRT–PCR was performed using the LightCycler Taqman master kit and the 
Universal Probe Library assay specific for SATB1, FOXP3, IL-5, IL-17-A, IFN- and beta-2 
microglobulin (B2M; Roche Diagnostics) on a LightCycler 480 II (Roche Diagnostics). For 
each experiment at least three technical replicates were performed. Results were normalized 
to B2M expression. PCR primer sequences are listed in table S3. 
 
Immunofluorescence microscopy. 




 Treg from female 
heterozygous DEREG x scurfy mice purified from thymus were fixed in cold 
paraformaldehyde for 10 min, washed with PBS, permeabilized with Triton-X and pre-
blocked in PBS containing 10% normal goat serum and 1% gelatine from cold water fish 
skin for 30 min. Slides were then incubated in combinations of primary antibodies (rabbit 
anti-GFP, mouse anti-FOXP3, mouse anti-SATB1-AF647) for 60 min, washed twice, and 
incubated with secondary antibodies (anti-rabbit-AF488, anti-mouse-AF555) for 60 min, 
stained with DAPI and fluorescence was examined using an Olympus FluoView FV1000 or 
Zeiss LSM 5 LIVE confocal microscope. 
 
qRT–PCR of murine Treg. 










Tconv FACS-purified from male DEREG and DEREG x scurfy mice, as well as SATB1-, 
control-, on non-transduced expanded Treg, respectively. Complementary DNA was 
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synthesized (Miltenyi Biotech). qPCR was performed using the LightCycler Taqman master 
kit and the Universal Probe Library assay (Roche Diagnostics) on a LightCycler 480 II 
(Roche Diagnostics). PCR primer sequences are listed in table S4. 
 
Chromatin immunoprecipitation, whole genome arrays, ChIP qPCR, and 
electromobility shift assays. 
 Expanded cord blood Treg were cultured overnight in X-Vivo 15 media supplemented 
with 20 mM HEPES, pH 7.4, 5% heat inactivated pooled human serum (Lonza), 2 mM 
glutamine and 100 U/ml rhIL-2 prior to re-stimulation (2 hours) with 1 µM Ionomycin 
(Sigma) before cross-linking for 10 minutes in 1% formaldehyde solution (50 mM HEPES 
KOH, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and 1% formaldehyde). Cell 
lysis, chromatin immunoprecipitation (ChIP) and DNA isolation steps for human FOXP3 




 cells per 
immunoprecipitation with either a rabbit anti-FOXP3 IgG1 (Novus Biochem) or ChIP grade 
control rabbit IgG1 Sera (Abcam). Chromatin shearing conditions consisted of 12 repeats of 
30 second pulses amplitude 90% with 90 seconds between pulses with a Misonix S-4000 
ultrasonic processor (Misonix) with a microtip. Total input chromatin was also purified from 
an aliquot (100 µl) of cross-linked material and the concentration determined using a 
Nanodrop UV spectrophotometer (Thermo Scientific). 
Amplification of immunoprecipitated and Input chromatin (10 ng) for labelling and 
hybridisation to either Affymetrix Human Tiling 2.0R or Human Promoter 1.0 arrays was 
achieved by whole genome amplification (WGA; Sigma GenomePlex WGA kit) adapted for 
Affymetrix labelling systems by the inclusion of 0.1 mM dUTP (Promega Corp) in the 
amplification reaction
13
. Amplified material was purified using a PCR clean up kit 
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(QIAGEN). Labelling and hybridization of amplified material was carried out at the 
Biomolecular Resource Facility (John Curtin School of Medical Research, Australian 
National University).  
Data were analyzed in MAT
14
. A false discovery rate (FDR) of 0.5% and a score of 
>100.0 was used to identify significantly enriched regions in FOXP3 immunoprecipitated 
material relative to input chromatin. Gene accessions were assigned to an individual ChIP 
region if the peak of the enriched region fell within a window beginning 5kb upstream of a 
transcription start site (TSS). Annotation information was obtained using gene accessions 
from both UCSC and NCBI, encompassing RefSeqs, mRNAs and miRNAs. Tiling array 
data can be accessed under GSE20995. 
Validation of FOXP3 binding to genomic regions was carried out by ChIP-qPCR. 
Reactions were performed using a RT2 SYBRgreen/ROX qPCR master mix 
(SABiosciences). The relative enrichment of target regions in FOXP3 immunoprecipitated 
material relative to input chromatin analysis was carried out using the 2
-ΔΔCT
 method. 
Immunoprecipitations using rabbit IgG were used to normalize for non-specific background. 
PCR primer sequences are listed in table S5. 
 
Gene-specific mRNA silencing, miRNA knockdown and agonistic miRNA. 
All siRNAs as well as the miRNA mimics and inhibitors were purchased from 
Biomers or Dharmacon. miRNA mimics were designed according to the sequences 
published in miRBase and resembling the double-stranded Dicer-cleavage products. 
miRNA-inhibitors were designed as single-stranded antisense 2’OM oligonucleotides15. 
These were used for transfection of freshly isolated primary human Treg with nucleofection 
as previously described
16
. For luciferase assays, HEK293T cells were transfected with both 
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the reporter plasmids and the small RNA duplexes using Lipofectamine 2000 in a 96-well 
format and luciferase activity was measured 24 h later. Sequences are listed in tables S6 and 
S7. 
 
In vitro suppression assays after FOXP3 silencing. 





cultured with PKH-26-labeled natural or induced Treg at indicated ratios in the presence of 




) in 96-well plates in X-
Vivo-15 medium supplemented with 10% FCS for 72 h. CFSE dilution was measured on a 
FACSCanto II flow cytometer. 
 
Cytokine cytometric bead array. 
IL-4 and IFN-gamma concentrations were measured using the human TH1/TH2 
cytokine kit II (BD Pharmingen). 
 
miRNA profiling and miRNA qRT–PCR. 
All RNA were extracted using TRIZOL (Invitrogen) and purified in our laboratory 
using standard methods. Sample amplification, labelling and hybridization on Illumina 
miRNA array matrix were performed with the human v1 MicroRNA Expression Profiling 
kit for all arrays in this study according to the manufacturer’s instructions (Illumina) using 
an Illumina BeadStation. All data analyses were performed by using Bioconductor for the 
statistical software R (http://www.r-project.org). Expression values were normalized and 
summarized by using the IlluminaGUI package
11
. From the resulting data sets we extracted a 
list of miRNAs with a significant different expression in Treg compared to Tconv. For 
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miRNA-specific qRT-PCR, total RNA from freshly isolated Treg and Tconv, FOXP3- or 
control-transduced Tconv, as well as control or FOXP3 siRNA tranfected freshly isolated Treg 
was extracted using TRIZOL. First strand complementary DNA for each miRNA assessed 
was synthesized by using the TaqMan MicroRNA RT kit and the corresponding miRNA 
specific kit (Applied Biosystems). Levels of miRNA were measured by qPCR using the 
TaqMan Universal PCR MasterMix (Applied Biosystems) on a LighCycler 480 II (Roche 
Diagnostics). Ubiquitously expressed U6 small nuclear RNA or miR-26b were used for 
normalization. 
 
Cloning of SATB1 3’UTR constructs. 
The SATB1 3’UTR was amplified by PCR using human genomic DNA as source 
material. The full length 3’UTR construct was amplified with primers SATB1 3’UTR F1 
and R1, covering the full 1.2 kB region. After digestion with Xho I and Not I the fragment 
was cloned into the psiCHECK II vector (Promega) to generate psiCHECK II–SATB1–
3'UTR. 
 
SATB1 3’UTR F1: ATACTCGAGGATAAAAGTATTTGTTTCGTT 
SATB1 3’UTR R1: ATAGCGGCCGCACGATACAAACAATTTTAA 
 
A mutated construct was generated with PCR-based mutagenesis or the QuikChange 
Lightning Multi Site-Directed mutagenesis kit (Stratagene) following the manufacturer’s 
conditions. MiRNA binding sites were changed by swapping four nucleotides in the seed 
region as follows: 
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miR-155 site at +333 3’UTR: AGCATTA to AGCTAAT 
Forward primer: TAATTACCTTCTGTGATTATGATT  
Reverse primer: GCTTGTTTGAGGCTCCGGAA 
 
miR-34a site at +538 3’UTR: CACTGCC to CACACGG 




miR-21 site I at +886 3’UTR: ATAAGCT to ATATCGA 




miR-21 site II at +932 3’UTR: ATAAGCT to ATATCGA 




miR-18a site at +961 3’UTR: CACCTTA to CACGAAT 





miR-7 site at +1012 3’UTR: GTCTTCC to GTCAAGG 




Cloning of SATB1 constructs with potential FOXP3 binding regions. 
The corresponding SATB1 genomic regions were amplified by PCR using human genomic 
DNA as source material. The full length FOXP3 binding site constructs were amplified with 
the following primers: 
 
FOXP3 BR1 (251 bp, -3947 - -3697) 
FOXP3 BR1 F1: ATATGGTACCATGCTCATTTATTCTGTT 
FOXP3 BR1 R1: ATATAAGCTTGAAATAAAATATTGTAAACA 
 
FOXP3 BR2 (401 bp, -3110 - -2710) 
FOXP3 BR2 F1: ATATGGTACCGCTATTAGAGTGATATATT 
FOXP3 BR2 R1: ATATAAGCTTGTTCATGTAAAAATAAAG 
 
FOXP3 BR3 (401 bp, +269 - +669) 
FOXP3 BR3 F1: ATATGGTACCGTGTTTCTGTTTCTAGATAG 
FOXP3 BR3 R1: ATATAGATCTGAGTTTCTTTTGAGTTACACGT 
 
FOXP3 BR4 (401 bp, +3336 - +3736) 
FOXP3 BR4 F1: ATATGGTACCGACTGAATTAAATATAATGG 
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FOXP3 BR4 R1: ATATAAGCTTTCCAAGTTGTTAAACTGCA 
 
FOXP3 BR5 (200 bp, +6303 - +6502) 
FOXP3 BR5 F1: ATATGGTACCTAATTTGTTTGGACACAA 
FOXP3 BR5 R1: ATATAAGCTTGCAATGAATGCAGAATTAC 
 
FOXP3 BR6 (117 bp, +6653 - +6769) 
FOXP3 BR6 F1: ATATGGTACCCACAGTGAATCTCTTGTG 
FOXP3 BR6 R1: ATATAAGCTTCTATCAAAAAGATGAAGAAGAA 
 
After digestion with Acc65 I and Hind III resp. Bgl II for FOXP3 BR 3 the fragments were 
cloned into the pGL4.24 vector with a minP element upstream of the potential binding motif 
and a destabilized downstream Firefly luciferase. 
Mutated constructs were generated with either PCR-based mutagenesis or the QuikChange 
Lightning Multi Site-Directed mutagenesis kit (Stratagene) following manufacturer’s 
conditions. FOXP3 binding regions were changed as follows: 
 
FOXP3 BR1  
 
FOXP3 BR1 site I + II at -3933: ATTCTGTTTATCATTTT to CGTGCGGCCGCAGGACA 





FOXP3 BR1 site III + IV at -3718: ATGTTTAC to GGTCCGTG 




FOXP3 BR2  
 
FOXP3 BR2 site I at -3001: GTAATGTAAACAGTGTG to TGTCCTGCGGCCGCACG 




FOXP3 BR2 site II at -2881: CAAAATGTTTATCTGAC to TCGTCCCTGCAGGCCGG 




FOXP3 BR2 site III at -2843: TGAAAAATAATTCTTGT to CGTGGCTGGCGAAGAGC 




FOXP3 BR2 site IV at -2733: AATATTCTTTATTTTTA to GCTGGCGGCGCCGCGCG 






FOXP3 BR2 site V at -2727: CTTTATTTTTACATGAA to GGCGCCGCGCGTGATTG 





FOXP3 BR3  
 
FOXP3 BR3 site I at +511: ATAATTGTTGTTACTGA to CGTGCGGCCGCAGGACA 




FOXP3 BR4  
 
FOXP3 BR4 site I at +3343: TTAAATATAATGGTTTT to CCGGCGCGCCACCGCGA 





FOXP3 BR4 site II at +3538: GGTAATGTTATTTTTTG to CATCCCTGCAGGGACCA 




FOXP3 BR4 site III at +3583: TAGCAGTAAAAAATCTG to GCTCGCGGCCGCCGAGT 




FOXP3 BR5  
 
FOXP3 BR5 site I at +6398: ATGTTTGC to CGGTCCGTG 
FOXP3 BR5 site I forward primer: ATACTGTATACTACTCATAGCAAA 
FOXP3 BR5 site I reverse primer: CACGGACCGAACTCACCATTTATCTTCAG 
 
FOXP3 BR6  
 
FOXP3 BR6 site I + II at +6670: GATTATTTATTT to TCGGCGGCCGCG 




FOXP3 BR6 site III at +6728: GATTATTTATTT to CCGGCGCGCCAC 
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Human embryonic kidney (HEK) 293T (ATCC CRL-11268) cells were maintained in 
DMEM containing 10% heat-inactivated fetal bovine serum.  
To assess regulation of SATB1 expression by binding of miRNA to the 3’UTR of 
SATB1, the 3'UTR of human SATB1 was amplified using PCR and cloned into the 
psiCHECK II vector (Promega) to generate psiCHECK II–SATB1–3'UTR (see above). To 
control for specific miRNA-binding, miRNA seed motifs were mutated using the 
QuickChange mutagenesis kit (Promega). These constructs were transfected into HEK293T 
cells in 96-well plates together with miRNA mimics for either miR-155, miR-7, miR-21, 
miR-34a, miR-18a or a scrambled control miRNA.  
To assess regulation of SATB1 expression by binding of FOXP3 to the genomic locus 
of SATB1, the six potential FOXP3 binding regions were amplified using PCR and cloned 
into the pGL4.24 vector with a minP element upstream of the potential binding motif and a 
destabilized downstream Firefly luciferase (see above). To control for specific FOXP3-
binding, FOXP3 binding motifs were mutated using the QuickChange mutagenesis kit 
(Promega). These constructs were transfected separately into HEK293T cells in 96-well 
plates together with control plasmid or plasmids expressing FOXP3 as well as a plasmid 
encoding renilla luciferase for normalization.  
Lysis and analysis were performed 24 hours post transfection using the Promega Dual 
Luciferase Kit. Luciferase activity was counted in a Mithras plate reader (Berthold). 
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Lentiviral vector production.  
For transduction of human T cells cDNA encoding SATB1 and FOXP3 were 
obtained from Open Biosystems and placed into the 2
nd
 position of a T2A expression vector 
as previously described
17
. High titer lentiviral vector supernatant encoding DsRED T2A 
SATB1, YFP T2A FOXP3 and control plasmids alone was collected as previously 
described
18
. For silencing of FOXP3 and SATB1 in human Treg, artificial miRNA against 
FOXP3 and SATB1 were designed, cloned into the pcDNA6.2-GW+EmGFP-miR vector, 
chained and recombined with pDONR221 and pLenti6.3 to generate miRNA containing 
pLenti6.3 expression vectors (all from Invitrogen). Oligonucleotide sequences are listed in 
table S11. For transduction of murine expanded Treg, SATB1 was cloned into the pLVTHM 
expression vector in front of an IRES-Thy1.1 sequence
19
. High titer lentiviral vector 





Lentiviral FOXP3 and SATB1 transductions of human CD4
+
 T cells. 
Treg-depleted human CD4
+
 Tconv were lentivirally transduced with a pELNS YFP T2A 
FOXP3 or control plasmids containing GFP as previously described
17
 and assessed after a 
resting period of 72-120 h for SATB1, FOXP3, cytokine gene, and Treg-cell associated gene 
expression, miRNA expression as well as whole genome expression analysis using Illumina 





 Treg were stimulated for 24 hours with CD3 and 
CD28-coated beads in the presence of IL-2. After this initial stimulation, Treg were 
lentivirally transduced with a pELNS DsRED 2A SATB1 or control plasmids containing 
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DsRED as previously described
17
 resulting in a 1:1 expression of DsRED and the 
transgene
2
, expanded for 6 days in the presence of CD3 and CD28-coated beads and IL-2, 
sorted on DsRED-positive cells on a MoFlo sorter (DakoCytomation) and used for 
suppression assays directly after isolation, cytokine assessment after 4 and 16 hours of 
CD3/CD28 stimulation, SATB1, FOXP3 and cytokine gene expression by qPCR and whole 





In vitro suppression assays of human SATB1-transduced Treg. 
Following the harvest of SATB1-transduced Treg, varying numbers of Treg were 
plated in round-bottom, 96-well plates (Corning). Frozen autologous PBMCs were thawed 
and CFSE labelled. 1 x 10
5
 CFSE-labelled PBMC were added together with CD3-coated 
beads (Invitrogen) at a ratio of one bead per cell
20
. Cultures were harvested 4 days later and 
stained with allophycocyanin-conjugated CD8 (BD Pharmingen). Data were acquired on a 
FACSCalibur (BD Biosciences) flow cytometer using CellQuest Pro software and analyzed 
using FlowJo software (Tree Star).  
 
Bisulphite sequencing. 
Genomic DNA from human Treg cells and conventional T cells purified by negative 
selection using CD4-RosetteSep (Stem Cell), followed by sorting on a FACSDiVa cell 
sorter (Becton Dickinson) after incubating cells with a combination of fluorochrome-
labelled monoclonal antibodies to CD4, CD25, and CD127 was isolated using 
phenol/chloroform extraction. Sodium bisulphate treatment of genomic DNA was performed 
resulting in the deamination of unmethylated cytosines to uracil, whereas methylated 
44 
cytosines remain unchanged. After amplification PCR products were purified and sequenced 
in both directions. PCR primer sequences are listed in tableS7. 
 
Filter retention analysis. 
Each individual 
32
P-radiolabeled dsDNA sequence (14 nM) was incubated with 
increasing concentrations of FOXP3 protein for 30 min at 37°C in 25 μl of binding buffer 
(KCl-Tris, pH 7.6, 5% Glycerol, 3 mM MgCl2, 2 mM DTT) in the presence of 1µg/ml tRNA 
(Roche) and 50µg/ml BSA. After incubation, the binding reaction was filtered through pre-
wet 0.45µm nitrocellulose filter membrane (Millipore) to co-retain protein and bound DNA. 
Membranes were washed and the amount of bound DNA-protein complexes determined by 
autoradiography
21
. Data analysis was done with Origin 8G software using non-linear curve 
fitting (Hill1-model). Oligonucleotide sequences are listed in table S9. 
 







 Treg were isolated from lymph nodes and spleens of DEREG mice. 
Cells were pre-enriched with the mouse CD4
+
 T-cell isolation kit according to 
manufacturer's instructions (Miltenyi Biotech). Following enrichment, cells were stained 
with CD4, CD25, CD3, and CD8. Cells were sorted on a FACS Aria III (BD) (purity > 
98.0%). Cells were expanded in vitro by activation with Dynabead mouse T cell activator 
CD3/CD28 coated microbeads (3:1 bead to Treg ratio, Invitrogen) with exogenous IL-2 




Lentiviral transductions of murine Treg cells. 
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After expansion for 10 to 14 days in the presence of CD3/CD28 coated beads and IL-
2, murine Treg were lentivirally transduced with a pLVTHM-SATB1-IRES-Thy1.1 plasmid 
or control plasmids. Therefore, 2.5×10
5
 cells per well were transduced in 500 µl total 
volume of fresh culture media in a 24-well plate containing lentivirus (20 TU/cell) and 
protamine sulfate (8 µg/ml; Sigma-Aldrich). Cells were spin-inoculated by centrifugation at 
1000×g for 90 min at 30°C, fresh medium was added and cells were incubated for an 
additional 2 hours at 37°C. Afterwards, cells were washed several times and cultivated in the 
presence of CD3/CD28 coated beads and IL-2. Transgene expression was assessed no earlier 
than 72 hours post-transduction. SATB1-Thy1.1-transduced, control-transduced or non-
transduced expanded Treg were sorted on GFP and Thy1.1 expression or GFP expression 
alone on a FACS Aria III (BD) and used for suppression assays, cytokine gene expression 
by qPCR or adoptive transfer experiments directly after isolation. 
 
In vitro suppression assays of murine SATB1-transduced Treg. 





, control transduced or non-transduced expanded Treg were 
plated in round-bottom 96-well plates. Freshly isolated splenic CD4
+
 T cells from C57BL/6 
mice were labelled with eFlour 670 (eBiosciences). 1 x 10
5
 eFlour 670-labelled CD4
+
 T 
cells were added together with CD3/CD28-coated beads (Invitrogen) at a ratio of one bead 
per 3 cells. Cultures were harvested 4 days later, acquired on a LSR II flow cytometer and 
analyzed using FlowJo software (Tree Star).  
 
Induction and assessment of colitis.  
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Splenocyte samples were enriched for CD4
+
 T cells by negative selection on MACS 
columns with the CD4
+
 T-cell isolation kit II (Miltenyi Biotec). Cells were then stained with 












 T cells that were purified from C57BL/6 mice into RAG2
-/-
 animals 









 T cells served as 










 T cells. Recipient mice were weighed 3 times per week and monitored for 
signs of illness. After 8 weeks, the animals were killed, and the mesenteric and peripheral 
LNs as well as spleen were analyzed by flow cytometry. For histological analysis, the large 
intestine (from the ileo-ceco-colic junction to the anorectal junction) was removed, fixed in 
10% buffered formalin solution, and routinely processed for histological examination. 
Sections were stained with hematoxylin and eosin and assigned scores as described (Zitat 
Claudia). All samples were coded and assigned scores by researchers 'blinded' to the 
experimental conditions. 
 


















Tconv were isolated on a FACS Aria III and plated at 2.5×10
5
 Treg or Tconv per well in a 24-
well plate and activated with CD3/ CD28 coated microbeads (Invitrogen) at a 3:1 bead to 
cell. Cultures were grown in the presence of IL-2 and continuing throughout the expansion 
period (300 IU/ml, Proleukin). Cells were resuspended and fresh media and IL-2 (300 
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IU/ml) added at days 5, 7, 9, and 12 assuming consumption of IL-2. On day 8, cells were 
restimulated with fresh CD3/CD28 coated beads. Cultured cells were harvested at day 14 for 
analysis by FACS (only cultures with >95% FOXP3 expression were used for further 
studies), functional studies, lentiviral transductions with miRNAs against FOXP3 and 
SATB1 as well as analysis of histone modifications.  
 
Lentiviral transductions of expanded human Treg. 
Expanded human Treg were lentivirally transduced with pLenti6.3-EmGFP-miRNA-
FOXP3, pLenti6.3-EmGFP-miRNA-FOXP3-miRNA-SATB1 or control plasmids containing 
EmGFP as previously described
17
, expanded for 3 further days in the presence of CD3 and 
CD28-coated beads and IL-2, sorted on EmGFP-positive cells on a FACS Aria III sorter 
(BD) and used directly after isolation for cytokine gene expression by qPCR or for cytokine 
assessment after 16 hours of CD3/CD28 stimulation. 
 
Assessment of histone modifications in expanded human CD4
+
 T cells 
ChIP-Seq experiments were performed as described previously. In brief, expanded Treg 
and Tconv were harvested on days 14, treated with MNase to generate approximately 80% 
mononucleosomes and 20% dinucleosomes. Chromatin from 2.5 × 10
6
 cells was used for 
each ChIP experiment, which yielded approximately 500 pg of DNA. Antibodies against 
histone H4Ac, H3K4me3 and H3K27me3 (Millipore) were used. The ChIP DNA fragments 
were blunt-ended, ligated to the Illumina adaptors, and sequenced with the Illumina HiScan. 
Sequenced reads of mostly 25 bp were obtained with the Solexa Analysis Pipeline. All reads 
were mapped to the human genome (hg18) using CASAVA 1.7 (Illumina) and only 
uniquely matching reads were retained. Data were further analyzed in MACS
23
. A false 
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discovery rate (FDR) of 0.5% and a p-value (-10log10) of >100.0 was used to identify 
significantly enriched regions in histone immunoprecipitated material from Treg relative to 
Tconv and vice versa at the SATB1 locus.  
Validation of histone binding to the SATB1 locus was carried out by ChIP-qPCR. 
Reactions were performed using SYBR green qPCR master mix (Fermentas). The relative 
enrichment of target regions in histone immunoprecipitated material relative to input 
chromatin analysis was carried out using the 2
-ΔΔCT
 method. Immunoprecipitations using 
control IgG were used to normalize for non-specific background. PCR primer sequences are 
listed in table S10. 
 To confirm histone modifications observed at the SATB1 locus in human expanded 
Treg, previously published murine data were reanalyzed for SATB1 expression and histone 









Table 1 Experimental conditions for microarray analysis 
ID n donor subset celltype experimental condition 
1 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 
2 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 + TGF- 
3 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 + VEGF 
4 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 + IL-10 
5 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 + PGE2  
6 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 + PD1 
7 4 healthy activated Tconv CD4+ 8 hrs CD3CD28 + CTLA-4 
8 4 healthy activated Tconv CD4+ 8 hrs CD3  
9 4 healthy activated Tconv CD4+ 24 hrs CD3/IL-2  
10 3 healthy TGF--treated Tconv CD4+ 18 hrs cultured + 1 hr TGF- 
11 3 healthy TGF--treated Tconv CD4+ 18 hrs cultured + 2 hrs TGF- 
12 3 healthy TGF--treated Tconv CD4+ 18 hrs cultured + 8 hrs TGF- 
13 4 healthy TGF--treated Tconv CD4+ 12 hrs cultured + 8 hrs TGF- (1ng/ml) 
14 4 healthy TGF--treated Tconv CD4+ 12 hrs cultured + 8 hrs TGF- (10ng/ml) 
15 3 healthy TGF--treated Tconv CD4+ 18 hrs TGF- 
16 4 healthy resting Tconv CD4+ 8 hrs cultured 
17 4 healthy resting Tconv CD4+ 12 hrs cultured 
18 3 healthy resting Tconv CD4+ 18 hrs cultured 
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19 3 healthy resting Tconv CD4+ 19 hrs cultured  
20 6 healthy resting Tconv CD4+ 20 hrs cultured  
21 3 healthy resting Tconv CD4+ 26 hrs cultured  
22 7 healthy resting Tconv CD4+ Untreated  
23 4 healthy resting Tconv CD4+CD25- Untreated 
24 2 healthy resting Tconv CD4+CD25- Untreated  
25 2 healthy resting Tconv CD4+CD25- Untreated  
26 3 healthy resting Tconv CD4+CD25- 6 hrs cultured 
27 2 healthy resting Tconv CD4+CD25- Untreated 
28 3 healthy resting Tconv CD4+CD25- Untreated 
29 3 healthy resting Tconv CD4+CD25- Untreated  
30 4 healthy resting Tconv CD4+CD25- Untreated  
31 4 CLL resting Treg CD4+CD25+ Untreated 
32 4 healthy resting Treg CD4+CD25+ Untreated  
33 4 healthy resting Treg CD4+CD25+ Untreated 
34 2 healthy resting Treg CD4+CD25+ Untreated  
35 2 healthy resting Treg CD4+CD25+ 6 hrs cultured 
36 4 healthy activated Treg CD4+CD25+ 24 hrs CD3/IL-2  
37 4 CLL activated Treg CD4+CD25+ 24 hrs CD3/IL-2  
38 4 healthy expanded Treg CD4+CD25+ expanded 
39 4 healthy expanded Treg CD4+CD25+ expanded with Rapamycin 



























B1 -19933 -18711 1223 9 7.05 154.29 BR1 7 -19337 -18711 626 
B2 -17526 -15898 1629 15 5.25 90.42 BR2 6 -16970 -16592 379 
B3 -15767 -14637 1131 7 5.16 87.58 BR3 2 -15692 -15439 254 
B4 -13165 -12161 1005 5 6.43 130.41 BR4 4 -22566 -12161 406 
B5 -12160 -11018 1143 8 4.89 79.92 BR5 4 -11490 -11217 274 
B6 -11017 -9639 1379 14 6.02 115.69 BR6 6 -10161 -9818 345 
B7 -8491 -6303 2189 13 6.88 147.33 BR7 4 -7085 -6865 221 
B8 -5995 -4369 1627 15 5.47 97.25 BR8 5 -5181 -4896 286 
B9 -4356 -1861 2496 27 12.86 483.42 BR9 4 -3947 -3697 251 
       BR10 5 -3110 -2710 401 
B10 -854 1465 2320 13 7.88 189.63 BR11 1 +269 +669 401 
B11 +2895 +6146 3252 29 7.96 193.47 BR12 3 +3336 +3736 401 
B12 +6505 +7653 1149 9 5.59 101.04 BR13 1 +6303 +6502 200 
       BR14 3 +6653 +6769 117 
B13 +11598 +13006 1409 12 6.93 149.36 BR15 7 +12260 +12760 501 
B14 +20356 +22256 1901 20 11.38 381.62 BR16 6 +21031 +21431 401 
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Table 3 human qPCR oligonucleotides 
SATB1 Forward CGATGAACTGAAACGAGCAG 
SATB1 Reverse CGGAGGATTTCTGAAAGCAA 
FOXP3 Forward ACCTACGCCACGCTCATC 
FOXP3 Reverse TCATTGAGTGTCCGCTGCT 
IL-5 Forward GGTTTGTTGCAGCCAAAGAT 
IL-5 Reverse TCTTGGCCCTCATTCTCACT 
IFN- Forward CACTGAAGAAATCTTTCAGGGAAT 
IFN- Reverse CCGTCTTTCTTCTCCACACTTT 
IL-17A Forward TGGGAAGACCTCATTGGTGT 
IL-17A Forward GGATTTCGTGGGATTGTGAT 
CTLA4 Forward TTCATCCCTGTCTTCTGCAA 
CTLA4 Reverse AGTGGCTTTGCCTGGAGAT 
GITR Forward AGGCCAGGGGGTACAGTC 
GITR Reverse AAGGTTTGCAGTGGCCTTC 
PDE3B Forward AACAATGGTATAAGCCTCATTATCAA 
PDE3B Reverse CGAGCCTCATTTAGCACTGA 
CD25 Forward ACGGGAAGACAAGGTGGAC 
CD25 Reverse TGCCTGAGGCTTCTCTTCA 
CD127 Forward AAAGTTTTAATGCACGATGTAGCTT 
CD127 Reverse TGTGCTGGATAAATTCACATGC 
CD73 Forward TGATCCTCCCAAACTTCCTG 
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CD73 Reverse AACCACGTTGATATCTTGGTCA 
CD39 Forward AAGGCCACAGCTGGCTTAC 
CD39 reverse GGAAAGGCGATGCTTTAAATAC 
GPR83 Forward TCTGCCAGAAATTATTTACCTTCA 
GPR83 Reverse AGCTGGCTCAGGGAAGTCT 
-2 microglobulin Forward TTCTGGCCTGGAGGCTAT 




Table 4 murine qPCR oligonucleotides 
satb1 Forward AGGAGTGCCCCCTTTCAC 
satb1 Reverse TGCTGCTGAGACATTTGCAT 
foxp3 Forward ACCACACTTCATGCATCAGC 
foxp3 Reverse CCAGTGGCAGCAGAAGGT 
IL-5 Forward CAAACTGGTAATGTAGCCAAGGAT 
IL-5 Reverse CTGTAACCTCAGCCTTCAGGA 
IL-6 Forward GCTACCAAACTGGATATAATCAGGA 
IL-6 Reverse CCAGGTAGCTATGGTACTCCAGAA 
IFN- Forward CCTTTGGACCCTCTGACTTG 
IFN- Reverse AGCGTTCATTGTCTCAGAGCTA 
-actin Forward CTAAGGCCAACCGTGAAAAG 




Table 5 ChIP-PCR oligonucleotides 
SATB1 BR1 Forward GAACAGTAGTACATTCATATACTGG 
SATB1 BR1 Reverse TTAAGATGCCTATTCATGCTATTCC 
SATB1 BR2 Forward GAAAGTTATGTTTCAGCATGATGAG 
SATB1 BR2 Reverse CTGGTATTTACTTCAGGAAGGTAAG 
SATB1 BR3 Forward TCAACACATTAACACACATTATTTC 
SATB1 BR3 Reverse ATAACTTGAAAGCATAAAAATAGGC 
SATB1 BR4 Forward CAAACAGAGCACTCCCCTGAG 
SATB1 BR4 Reverse GGAAAGAACGCATAGAAGGTCAATC 
SATB1 BR5 Forward TCTCATTTCCTCTTGTTTATTGTTG 
SATB1 BR5 Reverse ATAATAAGGTTAAGTAGGCTTCTCC 
SATB1 BR6 Forward TTCTACTGTGGCATTATTTATCAAC 
SATB1 BR6 Reverse GCATATCCAGTTACCTATCTTGTAG 
SATB1 BR7 Forward TCTCCCAAAACAAACATAAACATTG 
SATB1 BR7 Reverse TTTCCCTAATTACTTGGCATAGAT 
SATB1 BR8 Forward AAAGTGTTATGGTGGTAAGCATTG 
SATB1 BR8 Reverse CAGAGAAAGCATTTAGAATTCGAGTG 
SATB1 BR9 Forward ATAGTCATTCTTAGATGCCTTTATG  
SATB1 BR9 Reverse CTGTTGGGCAAAATAAAATTTAAAC 
SATB1 BR10 Forward ATTGGTGGCTTTACAGAGCTTAAT  
SATB1 BR10 Reverse AATTTGCTGGTAGGGAAAAGAGAA 
SATB1 BR11 Forward GTTTCAGGTCGGTTTTGCTAATTT  
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SATB1 BR11 Reverse GATTGTGCCCTTATCCATTCCATA  
SATB1 BR12 Forward TAGGCAGCTGTTTCTTCAAACTAA  
SATB1 BR12 Reverse CTGAAACTGCCCTACAACTAAGAA  
SATB1 BR13 Forward GCAGTAGAAAGGTGGGTTCTTC 
SATB1 BR13 Reverse GCAATGAATGCAGAATTACCTTT 
SATB1 BR14 Forward GCCTGTACTGTACCCAGTC  
SATB1 BR14 Reverse CATATTCAATGGCGTTTTCATAATG  
SATB1 BR15 Forward AGGTCAGCTATTACTTCTACCAGC  
SATB1 BR15 Reverse GGAAGGTAAAAATGCGCAAATCAG 
SATB1 BR16 Forward TTTTGTAGATGCTCTTGCTACCTC  
SATB1 BR16 Reverse TCATATGATCTACATGCTTGCGTT  
SATB1 -15kb ChIP Forward AGCAAGATTTAATTGCTGGTCCTG  
SATB1 -15kb ChIP Reverse TGCAATTGAAAAGACAAAGCCCTA 
CTLA4 Forward AAGGCTTTCTATTCAAGTGCCTTC 
CTLA4 Reverse TGTTCAGGTCTTCAGGAAGTAGAG 
PDE3B Intron 1 BS1 Forward GPH002163(+)02A 
PDE3B Intron 1 BS1 Reverse GPH002163(+)02A 
PDE3B Intron 1 BS2 Forward TATGCATTCCGTATGCGTGGTAG 
PDE3B Intron 1 BS2 Reverse AATGAACCTACAACAAGCAGCCT 
PDE3B Intron 10 Forward GTTTTGTGTGCAAACATGGGTCT 
PDE3B Intron 10 Reverse TGGAAAATGTTCTCAAGGTGGCT 
IL7RA Promoter Forward CAGGGAATATCCAGGAGGAA 
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IL7RA Promoter Reverse TGTGTGAGCCAGTGTGTATGAA 
AFM Intron 1 Forward GCAGAACCTAGTTCCTCCTTCAAC 
AFM Intron 1 Reverse AGTCATCCCTTCCTACAGACTGAGA  
hsa-miR-155 Forward TGCTAATCGTGATAGGGGTTTTTG 
hsa-miR-155 Reverse GCCTGAAGTCTAAGTTTATCCAGC  
hsa-miR-21 Forward CACCACAGGTAAGACTTTAATCCG 
hsa-miR-21 Reverse AAATGTGAGTGAGAGCTGTGAATG 
hsa-miR-7-1 Forward GPH026342(+)01A 




Table 6 siRNA 
FOXP3 sense GCACAUUCCCAGAGUUCCUdTdT 
FOXP3 antisense AGGAACUCUGGGAAUGUGCdTdT 
control sense UUCUCCGAACGUGUCACGUdTdT 
control antisense ACGUGACACGUUCGGAGAAdTdT 
SATB1 siRNA pool 1 sense GAAGGAAACACAGACAUUA 
SATB1 siRNA pool 1 antisense UAAUGUCUGUGUUUCCUUC 
SATB1 siRNA pool 2 sense GGAAUGCUCUGAAGGACUU 
SATB1 siRNA pool 2 antisense AAGUCCUUCAGAGCAUUCC 
SATB1 siRNA pool 3 sense GCAAAUGUCUCAGCAGCAA 
SATB1 siRNA pool 3 antisense UGCUGCUGAGACAUUUGC 
SATB1 siRNA pool 4 sense UCAGAAAUGUCUAACAAUG 




Table 7 miRNA mimics and inhibitors 
miR-155 guide UUAAUGCUAAUCGUGAUAGGGGU 
miR-155 passenger UCCUACAUAUUAGCAUUAACA 
miR-7 guide UGGAAGACUAGUGAUUUUGUUGU 
miR-7 passenger CAACAAAUCACAGUCUGCCAUA 
miR-21 guide UAGCUUAUCAGACUGAUGUUGA 
miR-21 passenger CAACACCAGUCGAUGGGCUGU 
miR-34a guide UGGCAGUGUCUUAGCUGGUUGU 
miR-34a passenger CAAUCAGCAAGUAUACUGCCCU 
miR-18a guide UAAGGUGCAUCUAGUGCAGAUAG 
miR-18a passenger ACUGCCCUAAGUGCUCCUUCUG 
control guide AAUUCUCCGAACGUGUCACGU 
control passenger GUGACACGUUCGGAGAAUUAC 
2'OM miR-155 ACCCCUAUCACGAUUAGCAUUAA 




Table 8 bisulphite sequencing oligonucleotides 
SATB1 CpG A Forward TCTCCCTGTGCCACCCAG 
SATB1 CpG A Reverse ACCACAATGGCACTAGGAC 
SATB1 CpG B Forward TAACTCCTCATAATTTAAAA 
SATB1 CpG B Reverse GGGAGTTATTAGGAAGTGGT 
SATB1 CpG C Forward CTCTCCCTATACCACCCAA 
SATB1 CpG C Reverse TATTATAATGGTATTAGGAT 
FOXP3 Forward TGTTGTAGGATAGGGTAGTT 




Table 9 oligonucleotides for filter retention  
SATB1 BR1 motif 3 sense GATGTAATAAGCATGTTTACAATATTTTATTTCAGTC 
SATB1 BR1 motif 3 antisense GACTGAAATAAAATATTGTAAACATGCTTATTACATC 
SATB1 BR1 motif 3 (mutated) sense GATGTAATTCAATTACGAATTGTATTTAATTTCAGTC 
SATB1 BR1 motif 3 (mutated) antisense GACTGAAATTAAATACAATTCGTAATTGAATTACATC 
SATB1 BR2 motif 1 sense TTAGATTTGTAATGTAAACAGTGTGCCTAAGAG 
SATB1 BR2 motif 1 antisense CTCTTAGGCACACTGTTTACATTACAAATCTAA 
SATB1 BR2 motif 1 (mutated) sense TTAGATTTAGTGTGGATAAATCATGCCTAAGAG  




Table 10 Histone ChIP-PCR oligonucleotides 
SATB1 -25kb Forward TTAATGGCGGTAAGTAGTAAGTTC 
SATB1 -25kb Reverse TAAGACCAGAGGAATCAGAGATC 
SATB1 -24kb Forward GCCCATGTGCTTTCTATACAAGAC 
SATB1 -24kb Reverse ACTCATCTGCTTCCCCAAGTTATC 
SATB1 -23kb Forward TCCCTCCTGCTTCCATAGTTTC 
SATB1 -23kb Reverse TTGGCAAGAAGTGTAGTTAGGTTC 
SATB1 -22kb Forward GCACACACACTACAGTAACC 
SATB1 -22kb Reverse CGCACTCCTCCTCTTGTC 
SATB1 -21kb Forward GTCCATGCCTGAGTGAGTTCTG 
SATB1 -21kb Reverse ACGAGGAGTGGGTGCTACG 
SATB1 -20kb Forward TGACCTCAGAAGACCAACAG 
SATB1 -20kb Reverse GAGAAAGTTCGCCAAGGAAG 
SATB1 -19kb Forward GGATTTCCCTCCTAAAGTAC 
SATB1 -19kb Reverse GGTCTTCTTTCTCTATCTTCC 
SATB1 -17.5kb Forward ACCTTCAGATATTTCAGAGAGCAG 
SATB1 -17.5kb Reverse AAGCACAAACCACACAAAACTG 
SATB1 -13.5kb Forward AGCAGTTAATCACAGAGGTAGTTC 
SATB1 -13.5kb Reverse TTGTCTAAGTAAGCCTAAGTCCAG 
SATB1 -9.5kb Forward TGTGTAGCATAGACTGGACTGTAG 
SATB1 -9.5kb Reverse GCCAAGCCTCAGAGAAACAATG 
SATB1 -6.5kb Forward TTGTGCTGCTTTAAGAGTGTAGAG 
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SATB1 -6.5kb Reverse TCCGCCAGTGACTGTGTTAG 
SATB1 -4kb Forward TCCCGTGATCTTTGTTTAGTGGTG 
SATB1 -4kb Reverse GCCAGGCAATGTCACCTCAAG 
SATB1 -3kb Forward TCAGGGTGCTAAAATGGTAGAAC 
SATB1 -3kb Reverse CACTTCTGCTGTAATCTAGGGTAG 
SATB1 -2kb Forward CCGCCTCACTCTAATCAAG 
SATB1 -2kb Reverse AAAGCCGAAAGACAAGTAAC 
SATB1 -1kb Forward CTTCTGATCTTCCTCCTCCTC 
SATB1 -1kb Reverse CTCTCCCTGCCCATTGAC 
SATB1 0kb Forward GTCGGTTTTGCTAATTTCACTCAG 
SATB1 0kb Reverse GCTGGATCGCCTCCTTCG 
SATB1 +1kb Forward ATGGGACCTCTATCAACGGTAAAC 
SATB1 +1kb Reverse GGGCAGCAATGTTAATCTGGAAG 
SATB1 +2kb Forward CACATCTTTGGCCCAAAACTTG 





Table 11 oligonucleotides for miRNAs against human SATB and FOXP3  
SATB1 miRNA sense TGCTGATTCACTGCATACTGCTGGTTGTTTTGGCCACTGACTGAC
AACCAGCAATGCAGTGAAT 
SATB1 miRNA antisense CCTGATTCACTGCATTGCTGGTTGTCAGTCAGTGGCCAAAACAAC
CAGCAGTATGCAGTGAATC 
FOXP3 miRNA sense TGCTGAAAGCACTTGTGCAGACTCAGGTTTTGGCCACTGACTGAC
CTGAGTCTACAAGTGCTTT 
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